Document Name: role of Miglyol 818 (Caprylic/Capric/Linoleic Triglyceride) in Eye Cream2
Document link: https://patents.google.com/patent/US8158134B1/en



US8158134B1 - Microemulsion preconcentrate, microemulsion and use thereof 
        - Google Patents





















































US8158134B1 - Microemulsion preconcentrate, microemulsion and use thereof 
        - Google Patents
Microemulsion preconcentrate, microemulsion and use thereof 
       

Download PDF
Info

Publication number
US8158134B1



US8158134B1
US10/110,212
US11021200A
US8158134B1
US 8158134 B1
US8158134 B1
US 8158134B1
 
 
 
US 11021200 A
US11021200 A
US 11021200A
US 8158134 B1
US8158134 B1
US 8158134B1
Authority
US
United States
Prior art keywords
composition according
fatty acid
omega
microemulsion
component
Prior art date
1999-10-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active, expires 2024-10-22


Application number
US10/110,212
Inventor
Andreas Supersaxo
Marc Antoine Weder
Hans Georg Weder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

    Vesifact AG
  
Original Assignee
Vesifact AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1999-10-20
Filing date
2000-10-20
Publication date
2012-04-17


Priority claimed from CH1912/99
external-priority


2000-10-20
Application filed by Vesifact AG
filed
Critical
Vesifact AG


2002-04-19
Assigned to VESIFACT AG
reassignment
VESIFACT AG
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors: SUPERSAXO, ANDREAS


2012-04-17
Application granted
granted
Critical


2012-04-17
Publication of US8158134B1
publication
Critical
patent/US8158134B1/en


Status
Active
legal-status
Critical
Current


2024-10-22
Adjusted expiration
legal-status
Critical

Links



USPTO



USPTO PatentCenter



USPTO Assignment



Espacenet



Global Dossier



Discuss




239000004530
micro-emulsion
Substances




0.000
title
claims
abstract
description
220


239000000203
mixture
Substances




0.000
claims
abstract
description
130


XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances


O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
claims
abstract
description
96


239000002245
particle
Substances




0.000
claims
abstract
description
52


235000021315
omega 9 monounsaturated fatty acids
Nutrition




0.000
claims
abstract
description
24


235000020665
omega-6 fatty acid
Nutrition




0.000
claims
abstract
description
24


150000003626
triacylglycerols
Chemical class




0.000
claims
abstract
description
18


ZQPPMHVWECSIRJ-KTKRTIGZSA-N
Oleic acid
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(O)=O
ZQPPMHVWECSIRJ-KTKRTIGZSA-N
0.000
claims
description
116


OYHQOLUKZRVURQ-IXWMQOLASA-N
Linoleic acid
Natural products


CCCCC\C=C/C\C=C\CCCCCCCC(O)=O
OYHQOLUKZRVURQ-IXWMQOLASA-N
0.000
claims
description
100


239000004480
active ingredient
Substances




0.000
claims
description
88


-1
fatty acid triglyceride
Chemical class




0.000
claims
description
74


239000005642
Oleic acid
Substances




0.000
claims
description
58


229920003171
Poly (ethylene oxide)
Polymers




0.000
claims
description
38


235000014113
dietary fatty acids
Nutrition




0.000
claims
description
32


239000000194
fatty acid
Substances




0.000
claims
description
32


WWZKQHOCKIZLMA-UHFFFAOYSA-N
Caprylic acid
Chemical compound


CCCCCCCC(O)=O
WWZKQHOCKIZLMA-UHFFFAOYSA-N
0.000
claims
description
24


239000001828
Gelatine
Substances




0.000
claims
description
24


229920000159
gelatin
Polymers




0.000
claims
description
24


235000019322
gelatine
Nutrition




0.000
claims
description
24


GHVNFZFCNZKVNT-UHFFFAOYSA-N
Decanoic acid
Chemical compound


CCCCCCCCCC(O)=O
GHVNFZFCNZKVNT-UHFFFAOYSA-N
0.000
claims
description
22


239000002552
dosage form
Substances




0.000
claims
description
22


235000020778
linoleic acid
Nutrition




0.000
claims
description
20


239000002253
acid
Substances




0.000
claims
description
18


238000005886
esterification reaction
Methods




0.000
claims
description
16


235000015112
vegetable and seed oil
Nutrition




0.000
claims
description
14


239000008158
vegetable oil
Substances




0.000
claims
description
14


239000005632
Capric acid (CAS 334-48-5)
Substances




0.000
claims
description
12


239000005635
Caprylic acid (CAS 124-07-2)
Substances




0.000
claims
description
12


125000004432
carbon atoms
Chemical group


C*

0.000
claims
description
12


125000003178
carboxy group
Chemical group


[H]OC(*)=O

0.000
claims
description
12


150000007513
acids
Chemical class




0.000
claims
description
10


229960002446
octanoic acid
Drugs




0.000
claims
description
10


229920005862
polyol
Polymers




0.000
claims
description
10


150000003077
polyols
Chemical class




0.000
claims
description
10


239000002537
cosmetic
Substances




0.000
claims
description
8


150000004665
fatty acids
Chemical class




0.000
claims
description
8


ACTIUHUUMQJHFO-UPTCCGCDSA-N
Coenzyme Q10
Chemical compound


COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
ACTIUHUUMQJHFO-UPTCCGCDSA-N
0.000
claims
description
6


150000001298
alcohols
Chemical class




0.000
claims
description
6


235000017471
coenzyme Q10
Nutrition




0.000
claims
description
6


229940110767
coenzyme Q10
Drugs




0.000
claims
description
6


125000002887
hydroxy group
Chemical group


[H]O*

0.000
claims
description
6


210000001519
tissues
Anatomy




0.000
claims
description
6


150000001735
carboxylic acids
Chemical class




0.000
claims
description
4


229920001222
biopolymer
Polymers




0.000
claims
4


239000003795
chemical substances by application
Substances




0.000
abstract
description
46


239000000126
substance
Substances




0.000
abstract
description
14


239000008346
aqueous phase
Substances




0.000
abstract
description
4


PMATZTZNYRCHOR-CGLBZJNRSA-N
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17
Chemical compound


CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O
PMATZTZNYRCHOR-CGLBZJNRSA-N
0.000
description
120


108010036949
Cyclosporine
Proteins




0.000
description
114


229960001265
ciclosporin
Drugs




0.000
description
114


235000010482
polyoxyethylene sorbitan monooleate
Nutrition




0.000
description
66


229920000053
polysorbate 80
Polymers




0.000
description
66


239000000047
product
Substances




0.000
description
64


229920002690
Polyoxyl 40 HydrogenatedCastorOil
Polymers




0.000
description
52


LFQSCWFLJHTTHZ-UHFFFAOYSA-N
ethanol
Chemical compound


CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
36


XLMXUUQMSMKFMH-UZRURVBFSA-N
2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate
Chemical compound


CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO
XLMXUUQMSMKFMH-UZRURVBFSA-N
0.000
description
32


238000004519
manufacturing process
Methods




0.000
description
32


239000007921
spray
Substances




0.000
description
32


230000000699
topical
Effects




0.000
description
28


238000003756
stirring
Methods




0.000
description
26


239000002775
capsule
Substances




0.000
description
24


235000019441
ethanol
Nutrition




0.000
description
24


229960000686
Benzalkonium Chloride
Drugs




0.000
description
20


ZGTMUACCHSMWAC-UHFFFAOYSA-L
disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate
Chemical compound


[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O
ZGTMUACCHSMWAC-UHFFFAOYSA-L
0.000
description
20


239000008363
phosphate buffer
Substances




0.000
description
20


239000008389
polyethoxylated castor oil
Substances




0.000
description
18


239000000243
solution
Substances




0.000
description
18


239000004094
surface-active agent
Substances




0.000
description
18


229920002685
Polyoxyl 35CastorOil
Polymers




0.000
description
16


229960001285
Quercetin
Drugs




0.000
description
16


REFJWTPEDVJJIY-UHFFFAOYSA-N
Quercetin
Chemical compound


C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1
REFJWTPEDVJJIY-UHFFFAOYSA-N
0.000
description
16


239000003921
oil
Substances




0.000
description
16


235000019198
oils
Nutrition




0.000
description
16


DNIAPMSPPWPWGF-UHFFFAOYSA-N
propylene glycol
Chemical compound


CC(O)CO
DNIAPMSPPWPWGF-UHFFFAOYSA-N
0.000
description
16


235000005875
quercetin
Nutrition




0.000
description
16


229930002344
quercetin
Natural products




0.000
description
16


239000000499
gel
Substances




0.000
description
14


OIQOAYVCKAHSEJ-UHFFFAOYSA-N
2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid
Chemical compound


OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O
OIQOAYVCKAHSEJ-UHFFFAOYSA-N
0.000
description
12


WVDDGKGOMKODPV-UHFFFAOYSA-N
benzyl alcohol
Chemical compound


OCC1=CC=CC=C1
WVDDGKGOMKODPV-UHFFFAOYSA-N
0.000
description
12


150000002148
esters
Chemical class




0.000
description
12


238000010438
heat treatment
Methods




0.000
description
12


239000012071
phase
Substances




0.000
description
12


229920000136
polysorbate
Polymers




0.000
description
12


VYPSYNLAJGMNEJ-UHFFFAOYSA-N
silicium dioxide
Chemical class


O=[Si]=O
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
0.000
description
12


108010036941
Cyclosporins
Proteins




0.000
description
10


238000009826
distribution
Methods




0.000
description
10


239000007924
injection
Substances




0.000
description
10


238000002347
injection
Methods




0.000
description
10


239000000902
placebo
Substances




0.000
description
10


238000003860
storage
Methods




0.000
description
10


CZBZUDVBLSSABA-UHFFFAOYSA-N
Butylated hydroxyanisole
Chemical compound


COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C
CZBZUDVBLSSABA-UHFFFAOYSA-N
0.000
description
8


NLZUEZXRPGMBCV-UHFFFAOYSA-N
Butylhydroxytoluene
Chemical compound


CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1
NLZUEZXRPGMBCV-UHFFFAOYSA-N
0.000
description
8


239000003963
antioxidant agent
Substances




0.000
description
8


235000006708
antioxidants
Nutrition




0.000
description
8


235000005687
corn oil
Nutrition




0.000
description
8


239000006071
cream
Substances




0.000
description
8


PMATZTZNYRCHOR-UHFFFAOYSA-N
cyclosporine A
Chemical compound


CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O
PMATZTZNYRCHOR-UHFFFAOYSA-N
0.000
description
8


RTZKZFJDLAIYFH-UHFFFAOYSA-N
diethyl ether
Chemical compound


CCOCC
RTZKZFJDLAIYFH-UHFFFAOYSA-N
0.000
description
8


125000005456
glyceride group
Chemical group




0.000
description
8


239000003978
infusion fluid
Substances




0.000
description
8


238000002356
laser light scattering
Methods




0.000
description
8


238000002360
preparation method
Methods




0.000
description
8


239000002562
thickening agent
Substances




0.000
description
8


150000003712
vitamin E derivatives
Chemical class




0.000
description
8


WQZGKKKJIJFFOK-GASJEMHNSA-N
D-Glucose
Natural products


OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
WQZGKKKJIJFFOK-GASJEMHNSA-N
0.000
description
6


QAQJMLQRFWZOBN-LAUBAEHRSA-N
L-ascorbyl-6-palmitate
Chemical compound


CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O
QAQJMLQRFWZOBN-LAUBAEHRSA-N
0.000
description
6


239000011786
L-ascorbyl-6-palmitate
Substances




0.000
description
6


WHNWPMSKXPGLAX-UHFFFAOYSA-N
N-Vinylpyrrolidone
Chemical compound


C=CN1CCCC1=O
WHNWPMSKXPGLAX-UHFFFAOYSA-N
0.000
description
6


210000003491
Skin
Anatomy




0.000
description
6


229940029983
VITAMINS
Drugs




0.000
description
6


229930003427
Vitamin E
Natural products




0.000
description
6


229940046009
Vitamin E
Drugs




0.000
description
6


229940021016
Vitamin IV solution additives
Drugs




0.000
description
6


239000000654
additive
Substances




0.000
description
6


235000010385
ascorbyl palmitate
Nutrition




0.000
description
6


LDVVMCZRFWMZSG-UHFFFAOYSA-N
captan
Chemical compound


C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21
LDVVMCZRFWMZSG-UHFFFAOYSA-N
0.000
description
6


229920002678
cellulose
Polymers




0.000
description
6


235000010980
cellulose
Nutrition




0.000
description
6


238000007865
diluting
Methods




0.000
description
6


239000000839
emulsion
Substances




0.000
description
6


239000012530
fluid
Substances




0.000
description
6


239000008103
glucose
Substances




0.000
description
6


230000002209
hydrophobic
Effects




0.000
description
6


239000004615
ingredient
Substances




0.000
description
6


239000007788
liquid
Substances




0.000
description
6


238000003760
magnetic stirring
Methods




0.000
description
6


238000002156
mixing
Methods




0.000
description
6


229940068196
placebo
Drugs




0.000
description
6


229920001223
polyethylene glycol
Polymers




0.000
description
6


239000002244
precipitate
Substances




0.000
description
6


239000011780
sodium chloride
Substances




0.000
description
6


HEMHJVSKTPXQMS-UHFFFAOYSA-M
sodium hydroxide
Chemical compound


[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
6


239000007787
solid
Substances




0.000
description
6


230000001225
therapeutic
Effects




0.000
description
6


238000005809
transesterification reaction
Methods




0.000
description
6


239000011782
vitamin
Substances




0.000
description
6


235000013343
vitamin
Nutrition




0.000
description
6


235000019165
vitamin E
Nutrition




0.000
description
6


239000011709
vitamin E
Substances




0.000
description
6


229930003231
vitamins
Natural products




0.000
description
6


239000001993
wax
Substances




0.000
description
6


HVYWMOMLDIMFJA-DPAQBDIFSA-N
(3Î²)-Cholest-5-en-3-ol
Chemical compound


C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2
HVYWMOMLDIMFJA-DPAQBDIFSA-N
0.000
description
4


ZCDMRPMKAQLWAO-PZLFCYFRSA-N
(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid
Chemical class


CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
ZCDMRPMKAQLWAO-PZLFCYFRSA-N
0.000
description
4


XXJWXESWEXIICW-UHFFFAOYSA-N
2-(2-Ethoxyethoxy)ethanol
Chemical compound


CCOCCOCCO
XXJWXESWEXIICW-UHFFFAOYSA-N
0.000
description
4


CTPDSKVQLSDPLC-UHFFFAOYSA-N
2-(oxolan-2-ylmethoxy)ethanol
Chemical compound


OCCOCC1CCCO1
CTPDSKVQLSDPLC-UHFFFAOYSA-N
0.000
description
4


VVQNEPGJFQJSBK-UHFFFAOYSA-N
2-methyl-2-propenoic acid methyl ester
Chemical compound


COC(=O)C(C)=C
VVQNEPGJFQJSBK-UHFFFAOYSA-N
0.000
description
4


HMFKFHLTUCJZJO-UHFFFAOYSA-N
2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate
Chemical compound


CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO
HMFKFHLTUCJZJO-UHFFFAOYSA-N
0.000
description
4


WPYMKLBDIGXBTP-UHFFFAOYSA-N
Benzoic acid
Chemical compound


OC(=O)C1=CC=CC=C1
WPYMKLBDIGXBTP-UHFFFAOYSA-N
0.000
description
4


229920002134
Carboxymethyl cellulose
Polymers




0.000
description
4


229920002301
Cellulose acetate
Polymers




0.000
description
4


229920003134
EudragitÂ® polymer
Polymers




0.000
description
4


229940012356
Eye Drops
Drugs




0.000
description
4


RFVNOJDQRGSOEL-UHFFFAOYSA-N
Glycol stearate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCO
RFVNOJDQRGSOEL-UHFFFAOYSA-N
0.000
description
4


229920003091
Methocelâ¢
Polymers




0.000
description
4


229940063121
Neoral
Drugs




0.000
description
4


229940033080
Omega-6 Fatty Acids
Drugs




0.000
description
4


229940100688
Oral Solution
Drugs




0.000
description
4


239000002202
Polyethylene glycol
Substances




0.000
description
4


229920001451
Polypropylene glycol
Polymers




0.000
description
4


HVUMOYIDDBPOLL-XWVZOOPGSA-N
Sorbitan monostearate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
HVUMOYIDDBPOLL-XWVZOOPGSA-N
0.000
description
4


AOBORMOPSGHCAX-UHFFFAOYSA-N
Tocophersolan
Chemical compound


OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C
AOBORMOPSGHCAX-UHFFFAOYSA-N
0.000
description
4


URAYPUMNDPQOKB-UHFFFAOYSA-N
Triacetin
Chemical compound


CC(=O)OCC(OC(C)=O)COC(C)=O
URAYPUMNDPQOKB-UHFFFAOYSA-N
0.000
description
4


229960002622
Triacetin
Drugs




0.000
description
4


DOOTYTYQINUNNV-UHFFFAOYSA-N
Triethyl citrate
Chemical compound


CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC
DOOTYTYQINUNNV-UHFFFAOYSA-N
0.000
description
4


NWGKJDSIEKMTRX-AAZCQSIUSA-N
[(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
NWGKJDSIEKMTRX-AAZCQSIUSA-N
0.000
description
4


NIXOWILDQLNWCW-UHFFFAOYSA-N
acrylic acid
Chemical compound


OC(=O)C=C
NIXOWILDQLNWCW-UHFFFAOYSA-N
0.000
description
4


239000000443
aerosol
Substances




0.000
description
4


235000010443
alginic acid
Nutrition




0.000
description
4


229920000615
alginic acid
Polymers




0.000
description
4


230000000111
anti-oxidant
Effects




0.000
description
4


230000003078
antioxidant
Effects




0.000
description
4


235000019445
benzyl alcohol
Nutrition




0.000
description
4


229960004217
benzyl alcohol
Drugs




0.000
description
4


210000004027
cells
Anatomy




0.000
description
4


239000001913
cellulose
Substances




0.000
description
4


239000003240
coconut oil
Substances




0.000
description
4


235000019864
coconut oil
Nutrition




0.000
description
4


230000036576
dermal application
Effects




0.000
description
4


150000002170
ethers
Chemical class




0.000
description
4


239000003889
eye drop
Substances




0.000
description
4


LYCAIKOWRPUZTN-UHFFFAOYSA-N
glycol
Chemical compound


OCCO
LYCAIKOWRPUZTN-UHFFFAOYSA-N
0.000
description
4


150000002430
hydrocarbons
Chemical class




0.000
description
4


239000000017
hydrogel
Substances




0.000
description
4


239000006210
lotion
Substances




0.000
description
4


CSNNHWWHGAXBCP-UHFFFAOYSA-L
mgso4
Chemical compound


[Mg+2].[O-][S+2]([O-])([O-])[O-]
CSNNHWWHGAXBCP-UHFFFAOYSA-L
0.000
description
4


239000004006
olive oil
Substances




0.000
description
4


235000008390
olive oil
Nutrition




0.000
description
4


230000003287
optical
Effects




0.000
description
4


239000003960
organic solvent
Substances




0.000
description
4


239000006072
paste
Substances




0.000
description
4


239000008194
pharmaceutical composition
Substances




0.000
description
4


229920001983
poloxamer
Polymers




0.000
description
4


229920001993
poloxamer 188
Polymers




0.000
description
4


229920000191
poly(N-vinyl pyrrolidone)
Polymers




0.000
description
4


229920000058
polyacrylate
Polymers




0.000
description
4


229920001888
polyacrylic acid
Polymers




0.000
description
4


229920001296
polysiloxane
Polymers




0.000
description
4


230000002265
prevention
Effects




0.000
description
4


229920005989
resin
Polymers




0.000
description
4


239000011347
resin
Substances




0.000
description
4


150000003839
salts
Chemical class




0.000
description
4


235000012239
silicon dioxide
Nutrition




0.000
description
4


KEAYESYHFKHZAL-UHFFFAOYSA-N
sodium
Chemical compound


[Na]
KEAYESYHFKHZAL-UHFFFAOYSA-N
0.000
description
4


239000011734
sodium
Substances




0.000
description
4


229910052708
sodium
Inorganic materials




0.000
description
4


FAPWRFPIFSIZLT-UHFFFAOYSA-M
sodium chloride
Chemical compound


[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
4


IBUIVNCCBFLEJL-UHFFFAOYSA-M
sodium;phosphoric acid;chloride
Chemical compound


[Na+].[Cl-].OP(O)(O)=O
IBUIVNCCBFLEJL-UHFFFAOYSA-M
0.000
description
4


150000003432
sterols
Chemical class




0.000
description
4


235000003702
sterols
Nutrition




0.000
description
4


125000002640
tocopherol group
Chemical group




0.000
description
4


229930003799
tocopherols
Natural products




0.000
description
4


QZCLKYGREBVARF-UHFFFAOYSA-N
tributyl 2-acetyloxypropane-1,2,3-tricarboxylate
Chemical compound


CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC
QZCLKYGREBVARF-UHFFFAOYSA-N
0.000
description
4


ZFOZVQLOBQUTQQ-UHFFFAOYSA-N
tributyl 2-hydroxypropane-1,2,3-tricarboxylate
Chemical compound


CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N
0.000
description
4


WEAPVABOECTMGR-UHFFFAOYSA-N
triethyl 2-acetyloxypropane-1,2,3-tricarboxylate
Chemical compound


CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC
WEAPVABOECTMGR-UHFFFAOYSA-N
0.000
description
4


239000001069
triethyl citrate
Substances




0.000
description
4


235000013769
triethyl citrate
Nutrition




0.000
description
4


239000003981
vehicle
Substances




0.000
description
4


229920002554
vinyl polymer
Polymers




0.000
description
4


239000002076
Î±-tocopherol
Substances




0.000
description
4


KZJWDPNRJALLNS-VPUBHVLGSA-N
(-)-beta-Sitosterol
Natural products


O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
KZJWDPNRJALLNS-VPUBHVLGSA-N
0.000
description
2


LNAZSHAWQACDHT-XIYTZBAFSA-N
(2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane
Chemical compound


CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC
LNAZSHAWQACDHT-XIYTZBAFSA-N
0.000
description
2


AXTGDCSMTYGJND-UHFFFAOYSA-N
1-dodecylazepan-2-one
Chemical compound


CCCCCCCCCCCCN1CCCCCC1=O
AXTGDCSMTYGJND-UHFFFAOYSA-N
0.000
description
2


BVDRUCCQKHGCRX-UHFFFAOYSA-N
2,3-dihydroxypropyl formate
Chemical compound


OCC(O)COC=O
BVDRUCCQKHGCRX-UHFFFAOYSA-N
0.000
description
2


SBASXUCJHJRPEV-UHFFFAOYSA-N
2-(2-Methoxyethoxy)ethanol
Chemical compound


COCCOCCO
SBASXUCJHJRPEV-UHFFFAOYSA-N
0.000
description
2


VUKAUDKDFVSVFT-UHFFFAOYSA-N
2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol
Chemical compound


COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O
VUKAUDKDFVSVFT-UHFFFAOYSA-N
0.000
description
2


JVKUCNQGESRUCL-UHFFFAOYSA-N
2-hydroxyethyl 12-hydroxyoctadecanoate
Chemical compound


CCCCCCC(O)CCCCCCCCCCC(=O)OCCO
JVKUCNQGESRUCL-UHFFFAOYSA-N
0.000
description
2


ICIDSZQHPUZUHC-UHFFFAOYSA-N
2-octadecoxyethanol
Chemical compound


CCCCCCCCCCCCCCCCCCOCCO
ICIDSZQHPUZUHC-UHFFFAOYSA-N
0.000
description
2


SGNBVLSWZMBQTH-ZRUUVFCLSA-N
24-epicampesterol
Chemical compound


C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](C)C(C)C)[C@@]1(C)CC2
SGNBVLSWZMBQTH-ZRUUVFCLSA-N
0.000
description
2


229910002012
AerosilÂ®
Inorganic materials




0.000
description
2


229910002014
AerosilÂ® 130
Inorganic materials




0.000
description
2


XJKJWTWGDGIQRH-BFIDDRIFSA-N
Alginic acid
Chemical compound


O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O
XJKJWTWGDGIQRH-BFIDDRIFSA-N
0.000
description
2


235000019489
Almond oil
Nutrition




0.000
description
2


229940114079
Arachidonic Acid
Drugs




0.000
description
2


YZXBAPSDXZZRGB-DOFZRALJSA-N
Arachidonic acid
Chemical compound


CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
YZXBAPSDXZZRGB-DOFZRALJSA-N
0.000
description
2


241000416162
Astragalus gummifer
Species




0.000
description
2


206010003816
Autoimmune disease
Diseases




0.000
description
2


VLPFTAMPNXLGLX-UHFFFAOYSA-N
Axona
Chemical compound


CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC
VLPFTAMPNXLGLX-UHFFFAOYSA-N
0.000
description
2


239000005711
Benzoic acid
Substances




0.000
description
2


SGNBVLSWZMBQTH-FGAXOLDCSA-N
Campesterol
Natural products


O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1
SGNBVLSWZMBQTH-FGAXOLDCSA-N
0.000
description
2


210000001736
Capillaries
Anatomy




0.000
description
2


229920000623
Cellulose acetate phthalate
Polymers




0.000
description
2


241000255580
Ceratitis <genus>
Species




0.000
description
2


229960004926
Chlorobutanol
Drugs




0.000
description
2


OSASVXMJTNOKOY-UHFFFAOYSA-N
Chlorobutanol
Chemical compound


CC(C)(O)C(Cl)(Cl)Cl
OSASVXMJTNOKOY-UHFFFAOYSA-N
0.000
description
2


229940107161
Cholesterol
Drugs




0.000
description
2


206010010741
Conjunctivitis
Diseases




0.000
description
2


208000010247
Contact Dermatitis
Diseases




0.000
description
2


SBJKKFFYIZUCET-JLAZNSOCSA-N
Dehydro-L-ascorbic acid
Chemical compound


OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O
SBJKKFFYIZUCET-JLAZNSOCSA-N
0.000
description
2


206010012442
Dermatitis contact
Diseases




0.000
description
2


JXTHNDFMNIQAHM-UHFFFAOYSA-N
Dichloroacetic acid
Chemical compound


OC(=O)C(Cl)Cl
JXTHNDFMNIQAHM-UHFFFAOYSA-N
0.000
description
2


229940095399
Enema
Drugs




0.000
description
2


241000792859
Enema
Species




0.000
description
2


239000001856
Ethyl cellulose
Substances




0.000
description
2


ZZSNKZQZMQGXPY-UHFFFAOYSA-N
Ethyl cellulose
Chemical compound


CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N
0.000
description
2


240000007842
Glycine max
Species




0.000
description
2


235000010469
Glycine max
Nutrition




0.000
description
2


229920002153
Hydroxypropyl cellulose
Polymers




0.000
description
2


AXISYYRBXTVTFY-UHFFFAOYSA-N
Isopropyl myristate
Chemical compound


CCCCCCCCCCCCCC(=O)OC(C)C
AXISYYRBXTVTFY-UHFFFAOYSA-N
0.000
description
2


XUGNVMKQXJXZCD-UHFFFAOYSA-N
Isopropyl palmitate
Chemical compound


CCCCCCCCCCCCCCCC(=O)OC(C)C
XUGNVMKQXJXZCD-UHFFFAOYSA-N
0.000
description
2


239000004166
Lanolin
Substances




0.000
description
2


229940039717
Lanolin
Drugs




0.000
description
2


210000000350
MC(T)
Anatomy




0.000
description
2


GHBFNMLVSPCDGN-UHFFFAOYSA-N
Monoctanoin
Chemical compound


CCCCCCCC(=O)OCC(O)CO
GHBFNMLVSPCDGN-UHFFFAOYSA-N
0.000
description
2


229940012843
Omega-3 Fatty Acids
Drugs




0.000
description
2


XAPRFLSJBSXESP-UHFFFAOYSA-N
Oxycinchophen
Chemical compound


N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1
XAPRFLSJBSXESP-UHFFFAOYSA-N
0.000
description
2


235000019482
Palm oil
Nutrition




0.000
description
2


235000019483
Peanut oil
Nutrition




0.000
description
2


229940066842
Petrolatum
Drugs




0.000
description
2


239000004264
Petrolatum
Substances




0.000
description
2


QCDWFXQBSFUVSP-UHFFFAOYSA-N
Phenoxyethanol
Chemical compound


OCCOC1=CC=CC=C1
QCDWFXQBSFUVSP-UHFFFAOYSA-N
0.000
description
2


229960005323
Phenoxyethanol
Drugs




0.000
description
2


229960000502
Poloxamer
Drugs




0.000
description
2


229940044519
Poloxamer 188
Drugs




0.000
description
2


239000004698
Polyethylene (PE)
Substances




0.000
description
2


229940113116
Polyethylene Glycol 1000
Drugs




0.000
description
2


229920002700
Polyoxyl 60 hydrogenated castor oil
Polymers




0.000
description
2


229920001213
Polysorbate 20
Polymers




0.000
description
2


229920001214
Polysorbate 60
Polymers




0.000
description
2


229940069328
Povidone
Drugs




0.000
description
2


229920003081
Povidone K 30
Polymers




0.000
description
2


RUOJZAUFBMNUDX-UHFFFAOYSA-N
Propylene carbonate
Chemical compound


CC1COC(=O)O1
RUOJZAUFBMNUDX-UHFFFAOYSA-N
0.000
description
2


102000007312
Recombinant Proteins
Human genes




0.000
description
2


108010033725
Recombinant Proteins
Proteins




0.000
description
2


229940100458
STEARETH-21
Drugs




0.000
description
2


229940005550
Sodium alginate
Drugs




0.000
description
2


229920001304
Solutol HS 15
Polymers




0.000
description
2


229940075582
Sorbic Acid
Drugs




0.000
description
2


229920002472
Starch
Polymers




0.000
description
2


229940032091
Stigmasterol
Drugs




0.000
description
2


HCXVJBMSMIARIN-MFBJGPNFSA-N
Stigmasterol
Natural products


O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@@H](/C=C/[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
HCXVJBMSMIARIN-MFBJGPNFSA-N
0.000
description
2


229940116362
Tragacanth
Drugs




0.000
description
2


229920001615
Tragacanth
Polymers




0.000
description
2


HWKQNAWCHQMZHK-UHFFFAOYSA-N
Trolnitrate
Chemical compound


[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O
HWKQNAWCHQMZHK-UHFFFAOYSA-N
0.000
description
2


239000004904
UV filter
Substances




0.000
description
2


206010046851
Uveitis
Diseases




0.000
description
2


229940099259
Vaseline
Drugs




0.000
description
2


IDGUCWCSGWRLPK-LLPUSWRMSA-N
[(2R)-2-[(2R,3R,4S)-3,4-di(octadecanoyloxy)oxolan-2-yl]-2-hydroxyethyl] octadecanoate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC
IDGUCWCSGWRLPK-LLPUSWRMSA-N
0.000
description
2


IYKJEILNJZQJPU-UHFFFAOYSA-N
acetic acid;butanedioic acid
Chemical compound


CC(O)=O.OC(=O)CCC(O)=O
IYKJEILNJZQJPU-UHFFFAOYSA-N
0.000
description
2


239000000783
alginic acid
Substances




0.000
description
2


229960001126
alginic acid
Drugs




0.000
description
2


239000008168
almond oil
Substances




0.000
description
2


239000003242
anti bacterial agent
Substances




0.000
description
2


230000003110
anti-inflammatory
Effects




0.000
description
2


230000002141
anti-parasite
Effects




0.000
description
2


230000001153
anti-wrinkle
Effects




0.000
description
2


235000021342
arachidonic acid
Nutrition




0.000
description
2


229960000892
attapulgite
Drugs




0.000
description
2


230000036621
balding
Effects




0.000
description
2


235000013871
bee wax
Nutrition




0.000
description
2


229940092738
beeswax
Drugs




0.000
description
2


239000000440
bentonite
Substances




0.000
description
2


229910000278
bentonite
Inorganic materials




0.000
description
2


229960004365
benzoic acid
Drugs




0.000
description
2


235000010233
benzoic acid
Nutrition




0.000
description
2


230000015572
biosynthetic process
Effects




0.000
description
2


235000000431
campesterol
Nutrition




0.000
description
2


239000004203
carnauba wax
Substances




0.000
description
2


235000013869
carnauba wax
Nutrition




0.000
description
2


239000000969
carrier
Substances




0.000
description
2


229940081734
cellulose acetate phthalate
Drugs




0.000
description
2


229940074979
cetyl palmitate
Drugs




0.000
description
2


239000007795
chemical reaction product
Substances




0.000
description
2


VEXZGXHMUGYJMC-UHFFFAOYSA-M
chloride anion
Chemical compound


[Cl-]
VEXZGXHMUGYJMC-UHFFFAOYSA-M
0.000
description
2


235000012000
cholesterol
Nutrition




0.000
description
2


238000001246
colloidal dispersion
Methods




0.000
description
2


150000001875
compounds
Chemical class




0.000
description
2


239000000470
constituent
Substances




0.000
description
2


229920001577
copolymer
Polymers




0.000
description
2


125000004122
cyclic group
Chemical group




0.000
description
2


201000004624
dermatitis
Diseases




0.000
description
2


231100000406
dermatitis
Toxicity




0.000
description
2


231100000080
dermatitis contact
Toxicity




0.000
description
2


229960005215
dichloroacetic acid
Drugs




0.000
description
2


229940075557
diethylene glycol monoethyl ether
Drugs




0.000
description
2


238000010790
dilution
Methods




0.000
description
2


125000000118
dimethyl group
Chemical group


[H]C([H])([H])*

0.000
description
2


235000020669
docosahexaenoic acid
Nutrition




0.000
description
2


230000035622
drinking
Effects




0.000
description
2


235000021271
drinking
Nutrition




0.000
description
2


239000003814
drug
Substances




0.000
description
2


229940079593
drugs
Drugs




0.000
description
2


230000002500
effect on skin
Effects




0.000
description
2


230000000694
effects
Effects




0.000
description
2


235000020673
eicosapentaenoic acid
Nutrition




0.000
description
2


239000007920
enema
Substances




0.000
description
2


FYUWIEKAVLOHSE-UHFFFAOYSA-N
ethenyl acetate;1-ethenylpyrrolidin-2-one
Chemical compound


CC(=O)OC=C.C=CN1CCCC1=O
FYUWIEKAVLOHSE-UHFFFAOYSA-N
0.000
description
2


235000019325
ethyl cellulose
Nutrition




0.000
description
2


229920001249
ethyl cellulose
Polymers




0.000
description
2


238000001704
evaporation
Methods




0.000
description
2


230000004634
feeding behavior
Effects




0.000
description
2


235000021285
flavonoid
Nutrition




0.000
description
2


YTAQZPGBTPDBPW-UHFFFAOYSA-N
flavonoid group
Chemical group


O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1
YTAQZPGBTPDBPW-UHFFFAOYSA-N
0.000
description
2


229930003935
flavonoids
Natural products




0.000
description
2


239000000796
flavoring agent
Substances




0.000
description
2


235000013355
food flavoring agent
Nutrition




0.000
description
2


238000005755
formation reaction
Methods




0.000
description
2


229940044550
gamma-Linolenic Acid
Drugs




0.000
description
2


235000020664
gamma-linolenic acid
Nutrition




0.000
description
2


229960002733
gamolenic acid
Drugs




0.000
description
2


PEDCQBHIVMGVHV-UHFFFAOYSA-N
glycerine
Chemical compound


OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
2


235000011187
glycerol
Nutrition




0.000
description
2


229940075529
glyceryl stearate
Drugs




0.000
description
2


125000004356
hydroxy functional group
Polymers


O*

0.000
description
2


235000010977
hydroxypropyl cellulose
Nutrition




0.000
description
2


239000001863
hydroxypropyl cellulose
Substances




0.000
description
2


235000010979
hydroxypropyl methyl cellulose
Nutrition




0.000
description
2


239000001866
hydroxypropyl methyl cellulose
Substances




0.000
description
2


229920003088
hydroxypropyl methyl cellulose
Polymers




0.000
description
2


229940031704
hydroxypropyl methylcellulose phthalate
Drugs




0.000
description
2


229920003132
hydroxypropyl methylcellulose phthalate
Polymers




0.000
description
2


230000001506
immunosuppresive
Effects




0.000
description
2


229910010272
inorganic material
Inorganic materials




0.000
description
2


239000011147
inorganic material
Substances




0.000
description
2


229940074928
isopropyl myristate
Drugs




0.000
description
2


229940075495
isopropyl palmitate
Drugs




0.000
description
2


235000019388
lanolin
Nutrition




0.000
description
2


239000004973
liquid crystal related substance
Substances




0.000
description
2


229910052943
magnesium sulfate
Inorganic materials




0.000
description
2


235000019341
magnesium sulphate
Nutrition




0.000
description
2


239000000463
material
Substances




0.000
description
2


229920000609
methyl cellulose
Polymers




0.000
description
2


235000010981
methylcellulose
Nutrition




0.000
description
2


239000001923
methylcellulose
Substances




0.000
description
2


239000002480
mineral oil
Substances




0.000
description
2


235000010446
mineral oil
Nutrition




0.000
description
2


230000001264
neutralization
Effects




0.000
description
2


235000015097
nutrients
Nutrition




0.000
description
2


239000007764
o/w emulsion
Substances




0.000
description
2


239000002674
ointment
Substances




0.000
description
2


150000002889
oleic acids
Chemical class




0.000
description
2


BARWIPMJPCRCTP-CLFAGFIQSA-N
oleyl oleate
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC
BARWIPMJPCRCTP-CLFAGFIQSA-N
0.000
description
2


235000020660
omega-3 fatty acid
Nutrition




0.000
description
2


239000006014
omega-3 oil
Substances




0.000
description
2


IAYPIBMASNFSPL-UHFFFAOYSA-N
oxane
Chemical class


C1CO1
IAYPIBMASNFSPL-UHFFFAOYSA-N
0.000
description
2


238000004806
packaging method and process
Methods




0.000
description
2


239000002540
palm oil
Substances




0.000
description
2


PXDJXZJSCPSGGI-UHFFFAOYSA-N
palmityl palmitate
Chemical compound


CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC
PXDJXZJSCPSGGI-UHFFFAOYSA-N
0.000
description
2


229910052625
palygorskite
Inorganic materials




0.000
description
2


239000012188
paraffin wax
Substances




0.000
description
2


239000000312
peanut oil
Substances




0.000
description
2


229940032051
peg-8 distearate
Drugs




0.000
description
2


235000019271
petrolatum
Nutrition




0.000
description
2


239000000546
pharmaceutic aid
Substances




0.000
description
2


230000000144
pharmacologic effect
Effects




0.000
description
2


229920000233
poly(alkylene oxides)
Polymers




0.000
description
2


229920000573
polyethylene
Polymers




0.000
description
2


235000010486
polyoxyethylene sorbitan monolaurate
Nutrition




0.000
description
2


229920002689
polyvinyl acetate
Polymers




0.000
description
2


229920002451
polyvinyl alcohol
Polymers




0.000
description
2


235000019422
polyvinyl alcohol
Nutrition




0.000
description
2


229920000915
polyvinyl chloride
Polymers




0.000
description
2


229920000036
polyvinylpyrrolidone
Polymers




0.000
description
2


235000013855
polyvinylpyrrolidone
Nutrition




0.000
description
2


108090000765
processed proteins & peptides
Proteins




0.000
description
2


102000004196
processed proteins & peptides
Human genes




0.000
description
2


125000001436
propyl group
Chemical group


[H]C([*])([H])C([H])([H])C([H])([H])[H]

0.000
description
2


108090000623
proteins and genes
Proteins




0.000
description
2


102000004169
proteins and genes
Human genes




0.000
description
2


201000004681
psoriasis
Diseases




0.000
description
2


VBICKXHEKHSIBG-UHFFFAOYSA-N
rac-1-monostearoylglycerol
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO
VBICKXHEKHSIBG-UHFFFAOYSA-N
0.000
description
2


150000004760
silicates
Chemical class




0.000
description
2


XUIMIQQOPSSXEZ-UHFFFAOYSA-N
silicon
Chemical compound


[Si]
XUIMIQQOPSSXEZ-UHFFFAOYSA-N
0.000
description
2


239000010703
silicon
Substances




0.000
description
2


229910052710
silicon
Inorganic materials




0.000
description
2


229920002545
silicone oil
Polymers




0.000
description
2


235000015500
sitosterol
Nutrition




0.000
description
2


229950005143
sitosterol
Drugs




0.000
description
2


230000037335
skin penetration
Effects




0.000
description
2


MSXHSNHNTORCAW-UHFFFAOYSA-M
sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate
Chemical compound


[Na+].OC1OC(C([O-])=O)C(O)C(O)C1O
MSXHSNHNTORCAW-UHFFFAOYSA-M
0.000
description
2


235000010413
sodium alginate
Nutrition




0.000
description
2


239000000661
sodium alginate
Substances




0.000
description
2


239000002904
solvent
Substances




0.000
description
2


WSWCOQWTEOXDQX-UHFFFAOYSA-N
sorbic acid
Chemical compound


CC=CC=CC(O)=O
WSWCOQWTEOXDQX-UHFFFAOYSA-N
0.000
description
2


235000010199
sorbic acid
Nutrition




0.000
description
2


239000004334
sorbic acid
Substances




0.000
description
2


239000003381
stabilizer
Substances




0.000
description
2


239000008107
starch
Substances




0.000
description
2


235000019698
starch
Nutrition




0.000
description
2


HCXVJBMSMIARIN-PHZDYDNGSA-N
stigmasterol
Chemical compound


C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2
HCXVJBMSMIARIN-PHZDYDNGSA-N
0.000
description
2


235000016831
stigmasterol
Nutrition




0.000
description
2


229940086735
succinate
Drugs




0.000
description
2


KDYFGRWQOYBRFD-UHFFFAOYSA-L
succinate(2-)
Chemical compound


[O-]C(=O)CCC([O-])=O
KDYFGRWQOYBRFD-UHFFFAOYSA-L
0.000
description
2


UEUXEKPTXMALOB-UHFFFAOYSA-J
tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate
Chemical compound


[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O
UEUXEKPTXMALOB-UHFFFAOYSA-J
0.000
description
2


239000011732
tocopherol
Substances




0.000
description
2


235000010384
tocopherol
Nutrition




0.000
description
2


235000019149
tocopherols
Nutrition




0.000
description
2


235000010487
tragacanth
Nutrition




0.000
description
2


239000000196
tragacanth
Substances




0.000
description
2


LADGBHLMCUINGV-UHFFFAOYSA-N
tricaprin
Chemical compound


CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC
LADGBHLMCUINGV-UHFFFAOYSA-N
0.000
description
2


235000013311
vegetables
Nutrition




0.000
description
2


KZJWDPNRJALLNS-VJSFXXLFSA-N
Î²-Sitosterol
Chemical compound


C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2
KZJWDPNRJALLNS-VJSFXXLFSA-N
0.000
description
2


VZCCETWTMQHEPK-QNEBEIHSSA-N
Î³-Linolenic acid
Chemical compound


CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O
VZCCETWTMQHEPK-QNEBEIHSSA-N
0.000
description
2



Classifications




A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K9/00—Medicinal preparations characterised by special physical form


A61K9/10—Dispersions; Emulsions


A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles


A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers








A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K38/00—Medicinal preparations containing peptides


A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof


A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C


A61K38/13—Cyclosporins







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K9/00—Medicinal preparations characterised by special physical form


A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate


A61K9/4841—Filling excipients; Inactive ingredients


A61K9/4858—Organic compounds







Abstract

The invention relates to compositions in the form of microemulsion preconcentrates that contain (a) a mixture that consists of a medium-chain triglyceride and an omega-9 fatty acid and/or an omega-6 fatty acid; and (b) a surface-active component that contains a polyoxethylene tenside. When contacted with water or with an aqueous medium these microemulsion preconcentrates form microemulsions. The microemulsions of the O/W type have an average particle size below 150 nm, preferably below 100 nm. The inventive microemulsion preconcentrates and microemulsions are suitable for use as vehicles for substances, namely active agents, that are hardly soluble in water, but soluble in components (a) and/or (b). In the aqueous phase, said microemulsions may contain water-soluble substances.




Description

BACKGROUND
The present invention relates to a new composition and the use thereof.
In a preferred embodiment form of the present invention there is an active ingredient poorly soluble in water. Cyclosporins are an example of such poorly soluble active ingredients.
Cyclosporins comprise a class of cyclic poly-N-methylated undecapeptides, whose representatives have pharmacological properties, in particular immuno-suppressive, anti-inflammatoric and/or anti-parasitic properties. The most famous of representatives of this class is cyclosporin A which is the active ingredient of the commercially available preparations SANDIMMUN and NEORAL.
Cyclosporins are neutral lipophilic (i.e. hydrophobic) substances with a low water solubility. Formulations of cyclosporins, e.g. for oral administration, are based mainly on the use of ethanol and oils or similar auxiliary agents as carrier media. Thus according to the Journal of Drug Targeting, 1998, Vol. 5, No. 6, pages 443-458 (in particular pages 447 and 448) the commercially available preparation SANDIMMUN is obtainable in three different forms, specifically
soft gelatine capsules, containing cylcosporine A, water-free ethyl alcohol (up to 12.7%), Labrafil M 2125 CS (polyoxyethylated glycolisated glycerides), maize oil and further ingredients;
an oral solution, containing cyclosporin A, ethyl alcohol (up to 12.5%), olive oil, Labrafil M 1944 CS (polyoxyethylated oleic acid glyceride); and further ingredients; and
an injection preparation, containing cyclosporin A, ethyl alcohol (32.9%) and Cremophor EL (polyethoxylated risinus oil); and the commercially available preparation NEORAL in two forms, specifically
soft gelatine capsules, containing cyclosporin A, water-free ethyl alcohol (up to 9.5%), maize oil glycerides, Cremophor RH 40 (polyoxyethylated hydrated risinus oil), propylene glycol and further ingredients; and
an oral solution, containing cyclosporin A, water-free ethyl alcohol (up to 9.5%), maize oil glycerides, Cremophor RH 40, propylene glycol and further excipients.
From DE 39 30 928 C2 there are known formulations which contain a cyclosporin as an active ingredient; a hydrophilic phase, specifically a pharmaceutically acceptable C1-C5-alkyl- or tetrahydrofurfuryl-diether or -partial ether of a low-molecular mono- or polyoxy-C2-C12-alkanediol, preferably transcutol (diethylene glycol mono ethyl ether) or glycofurol(tetrahydrofufurylalcohol polyethylene glycol ether) and/or 1,2-propylene glycol; a lipophilic phase; and a surface-active agent. The hydrophilic phase may additionally also contain further components, for example lower alkanols, such as ethanol.
From WO 99/00002 A there are known formulations which contain cyclosporin as an active ingredient; a polycarboxylic acid ester and/or a polyolcarboxylic acid ester; an oil; and a surface-active agent. The polycarboxylic acid esters are hereby esterification products of polycarboxylic acids with 2-10, preferably 3-5 carboxyl groups with C1-C10 alcohols, such as triethyl citrate, tributyl citrate, acetyltributyl citrate and acetyltriethyl citrate, and the polyolcarboxylic acids are hereby esterification products of polyols with 2-10, preferably 3-5 hydroxyl groups with C2-C11-carboxylic acids, such as e.g. triacetine.
SUMMARY OF THE INVENTION
As the above-discussed, known formulations, the formulations according to the present invention are microemulsion preconcentrates or microemulsions.
A microemulsion preconcentrate is to be understood as a system which on contact with water, e.g. with the addition of water, gives a microemulsion. Such a microemulsion is within the conventionally acknowledged meaning, a non-opaque or practically non-opaque colloidal dispersion, which contains water and organic components with the inclusion of lipophilic (i.e. hydrophobic) components.
Micro-emulsions may be recognised in that they have one or more of the following properties:
They are formed spontaneously when their components are brought into contact with one another; for this practically no supply of energy is necessary, and the formation of such microemulsions is therefore effected without heating or the application or a high shear force or other significant through-mixing.
They are practically non-opaque, specifically transparent or opalescent when they are observed under an optical microscope: in their non-disturbed condition they are optically isotropic although when observed for example with the use of X-ray irradiation technology one may ascertain an anisotropic structure.
They contain a disperse or particulate (droplet) phase, whose particles have a size of less than 200 nm, from which their optical transparency originates. The particles may be spherical or have other structures; for example they may be liquid crystals with lamellar, hexagonal or isotropic symmetries. Generally microemulsions contain droplets or particles with a maximal dimension, for example a diameter, of less than 150 nm, usually about 10-100 nm.
The microemulsion preconcentrates according to the invention are accordingly above all systems which contain an active ingredient which is poorly soluble in water, such as a cyclosporin, and which on bringing together with water are spontaneously or practically spontaneously i.e. without significant application of energy, capable of forming a microemulsion.
The microemulsion preconcentrates according to the invention are above all characterised in that they contain
(a) a mixture consisting of a medium-chain tri glyceride and an omega-9 fatty acid and/or an omega-6 fatty acid and
(b) a surface-active component containing a tenside of the polyoxethylene type. Such preconcentrates contain preferably as a component (c) an active ingredient which is poorly soluble in water but soluble in component (a) and/or (b).
In contrast to the formulations according to DE 39 30 928 C2 and WO 99/00002 A they may be essentially free of components which are mixable with water or soluble in water. Such components are in particular
  (a) C1-C5-alkyl- or tetrahydrofurfuryl-diethers or -partial ethers of low molecular mono- or polyoxy-C2-C12-alkanediols; (b) 1,2-propylene glycol; (c) lower alkanols; (d) esterification products of polycarboxylic acids with 2-10, in particular 3-5 carboxyl groups with C1-C10 alcohols; and (e) esterification products of polyols with 2-10, in particular 3-5 carboxyl groups with C2-C11 carboxylic acids;

in particular free of diethylene glycol monomethyl ether, glycofurol, 1,2-propylene glycol, triethyl citrate, tributyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, triacetine, ethanol, polyethylene glycol, dimethyl isosorbite and propylene carbonate.
 
As component (a) mixtures of a medium-chain fatty acid triglyceride, usefully of a fatty acid triglyceride in which the fatty acid radicals comprise 4-18, preferably 6 to 18 C-atoms, and of an omega-9 and/or omega-6 fatty acid are suitable. These substances are not mixable with water or are insoluble or practially insoluble in water and have no or practically no surface-active function.
Preferred medium-chain fatty acid tri glycerides are caprylic/capric acid triglycerides, as they are known for example under the trade description MIGLYOL and are obtainable on the market (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 808 to 809, 1989). To this belong for example the following products:
MIGLYOL 810
This is a fractionated coconut oil which contains triglycerides of caprylic acid and capric acid and has a molecular weight of about 520. It comprises a fatty acid composition with C6 (maximum 2 percent, C8 (about 65 to 75 percent), C10 (about 25 to 35 percent) and C12 (maximum 2 percent).

MIGLYOL 812

This is a fractionated coconut oil which contains triglycerides of caprylic acid and capric acid and has a molecular weight of about 520. It comprises a fatty acid composition with C6 (maximum 3 percent), C8 (about 50 to 65 percent), C10 (about 30 to 45 percent) and C12 (maximum 5 percent).

MIGLYOL 818

These are triglycerides of caprylic acid, capric acid and linoleic acid with a molecular weight of about 510. It comprises a fatty acid composition with C6 (maximum 3 percent), C8 (about 45 to 60 percent), C10 (about 25 to 40 percent), C12 (about 2 to 5 percent) and C182 (about 4 to 6 percent).

Furthermore also triglycerides of caprylic acid and capric acid are suitable, as are known and obtainable under the product description MYRITOL (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 834, 1989). To these there belongs for example the product MYRITOL 813.
Further suitable products of this class are CAPTEX 355, CAPTEX 300, CAPTEX 800, CAPMUL MCT, NEOBEE M5 and MAZOL 1400.
Suitable omega-9 fatty acids are mainly those with 12-24, in particular 16-24, preferably 18-22 C-atoms, for example oleic acid and eicosatrienic acid. Particularly preferred is oleic acid.
Suitable omega-6 fatty acids are mainly those with 12-24, in particular 16-24, preferably 18-22 C-atoms, for example linoleic acid, gamma-linolenic acid, dihommo-gamma-linoleic acid and arachidonic acid. Particularly preferred is linoleic acid.
In a particularly preferred embodiment form as component (a) one uses a mixture consisting of a caprylic/capric acid-triglyceride, oleic acid and/or linoleic acid.
Component (c), the therapeutic active ingredient which is poorly soluble in water but soluble in component (a) and/or (b) is for example a cyclosporin, preferably cyclosporin A or another suitable cylcosporin, for example another natural cyclosporin; one of the various non-natural cyclosporin derivatives or a synthetic cyclosporin.
Component (b), the surface-active component containing a tenside of the polyoxethylene type, can be a hydrophilic surface-active agent or a lipophilic surface-active agent, but also mixtures of such agents may be considered.
Examples of such tensides are the following:
reaction products of natural or hydrated vegetable oils and ethylene glycol, specifically polyoxyethylene-glycolated natural or hydrated vegetable oils, such as polyoxyethylene-glycolated natural or hydrated risinus oils. Particularly suitable are the various tensides which are known and obtainable under the description CREMOPHOR (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 326 to 327, 1989), above all the products with the descriptions CREMOPHOR RH 40, CREMOPHOR RH 60 and CREMOPHOR EL. Furthermore as such products also the various tensides which are known and obtainable under the description NIKKOL, for example NIKKOL HCO-60 are suitable.
polyoxyethylene sorbitane fatty acid esters, for example the mono- and triauryl ester, the mono- and tripalmityl ester, the mono- and tristearyl ester and the mono- and trioleylester as they are known and obtainable under the description TWEEN (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 1300 to 1304, 1989), for example the products
TWEEN 20: polyoxyethylene (20) sorbitane monolaurate,
TWEEN 40: polyoxyethylene (20) sorbitane monopalmitate,
TWEEN 60: polyoxyethylene (20) sorbitane monostearate,
TWEEN 80: polyoxyethylene (20) sorbitane monooleate,
TWEEN 65: polyoxyethylene (20) sorbitane tristearate,
TWEEN 85: polyoxyethylene (20) sorbitane trioleate,
TWEEN 21: polyoxyethylene (4) sorbitane monolaurate,
TWEEN 61: polyoxyethylene (4) sorbitane monostearate, and
TWEEN 81: polyoxyethylene (4) sorbitane monooleate.
Particularly preferred from this class of compounds is TWEEN 80.
    polyoxyethylene fatty acid esters, for example the polyoxyethylene stearic fatty acid esters known and obtainable on the market under the description MYRJ (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 834, 1989), in particular the product MYRJ 52, as well as also the polyoxyethylene fatty acid ester known and obtainable under the description CETIOL HE (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 284, 1989). copolymerisates of polyoxyethylene and polyoxypropylene, such as those which are for example known under the description PLURONIC and EMKALYX (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 956 to 958, 1989), in particular the product PLURONIC F68. block copolymerisates of polyoxyethylene and polyoxypropylene, as they are for example known and obtainable under the description POLOXAMER (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 959, 1989), in particular the product POLOXAMER 188. polyethoxylated vitamin E derivatives, in particular the product VITAMIN E TPGS (d-alpha tocoperyl polyethylene glycol 1000 succinate, Eastman). polyethoxylated hydroxy fatty acid ester, in particular the product SOLUTOL HS 15 (polyoxyethylene-660-hydroxystearate, BASF).   
transesterification products of natural vegetable oil glycerides and polyethylene polyols. To these there belong transesterification products of various, for example non-hydrated vegetable oils such as maize oil, kernel oil, almond oil, peanut oil, olive oil and palm oil, as well as of mixtures of these with polyethylene glycols, in particular with those which have an average molecular weight of 200-800. Various such transesterification products are known and obtainable under the description LABRAFIL (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 707; 1989); of these the products LABRAFIL M 1944 CS and LABRAFIL M 2130 CS are particularly suitable.
    ethylene oxide adducts of sterols and derivatives thereof, for example of cholesterol and derivatives thereof, such as products which are derived from sitosterol, campesterol or stigmasterol, for example of soya sterols and derivatives of these (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 554 and 555; 1989) as they are known and obtainable under the descriptions GENEROL, in particular the products GENEROL 122 E5, 122 E10 and 122 E25.   
The microemulsion preconcentrates according to the invention comprise systems which contain a single surface-active agent as well as systems which contain a mixture of two or more surface-active agents, e.g. TWEEN 80+CREMOPHOR RH 40, TWEEN 80+CREMOPHOR RH 40+VITAMIN E TPGS etc.
According to the invention one preferably uses a surface-active component which contains a polyoxyethylene sorbitane fatty acid ester, a polyoxyethylene-glycolated natural or hydrated vegetable oil or mixtures thereof.
The microemulsion preconcentrates according to the invention may also further contain additional substances, such as e.g. antioxidants, thickening agents, odoriferous agents and flavouring agents, colourings, etc.
As antioxidants for example ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols, e.g. D, L-alpha-tocopherol (vitamin E) are suitable.
As a thickening agent various pharmaceutically acceptable polymeric and inorganic materials are suitable, such as
    polyacrylate resins and copolymeric polyacrylate resins, as they are for example known and obtainable under the description CARBOPOL and EUDRAGIT (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 254 to 256 or 486 to 487, 1989), in particular the products CARBOPOL 934, 940 and 941 or EUDRAGIT E, L, S, RL and RS. celluloses and cellulose derivatives, such as methyl cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate succinate and hydroxypropyl methyl cellulose phthalate as well as salts thereof. Examples of such products are the products known and obtainable under the descriptions KLUCEL and METHOCEL (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 688 and 790, 1989), in particular the products KLUCEL LF, MF, GF and HF and METHOCEL K 100, K 15M, K 100M, E 5M, E 15, E 15M and E 100M. polyvinyl pryrrolidones, including for example poly-N-vinyl pyrrolidones and vinyl pryrrolidone copolymerisates such as vinyl pyrrolidone vinylacetate copolymerisates. Examples of such products are known and obtainable under the description KOLLIDON (described also in the USA as POVIDONE) (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 694 to 696, 1989), in particular the products KOLLIDON 30 and 90. polyvinyl resins, including for example polyvinyl acetates and polyvinyl alcohols, as well as also other polymeric materials such as tragacanth rubber, rubber arabicum, and alginates, e.g. alginic acid and salts thereof, such as sodium alginate. inorganic thickening agents, such as attapulgite, bentonite and silicates, including hydrophobic silicon dioxides, such as alkylated, for example methylated silicon dioxide gels, in particular colloidal silicon dioxides as they are known and obtainable under the description AEROSIL (Handbook of Pharmaceutical Excipients, publisher American Pharamaceutical Association/The Pharmaceutical Society of Great Britain, pages 253 to 256, 1986), in particular the products AEROSIL 130, 200, 300, 380, 0, OX 50, TT 600, MOX 80, MOX 170, LK 84 and the methylated AEROSIL R 972.   
If it is planned, in particular for the purpose of oral administration, that the compositions according of the invention be suitable end dosage forms for the direct administration, then according to the present invention also pharmaceutical compositions may be provided which contain a therapeutic active ingredient poorly soluble in water but soluble in component (a) and/or (b) and which themselves are microemulsions; in these microemulsions the active ingredient is to be solubilised in a stable manner, wherein over several weeks there are observed no precipitates. For an oral administration microemulsions which one for example obtains by diluting the microemulsion preconcentrates with water or with an aqueous medium, may be applied directly as drink formulations. If there is envisaged a topical or parenteral application then compositions, in which further auxiliary agents may be present, likewise contain water so that there results an aqueous microemulsion in the form of a spray, gel, a paste, a cream, an injection solution, an infusion solution or likewise. Such pharmaceutical compositions in the form of microemulsions are likewise new and the subject-matter of the present invention.
The microemulsions are above all characterised in that they are obtainable by mixing a microemulsion preconcentrate containing
  (a) a mixture consisting of a medium-chain triglyceride and an omega-9-fatty acid and/or an omega-6 fatty acid; (b) a surface-active component containing a tenside of the polyoxethylene type; (c) an active ingredient poorly soluble in water but soluble in component (a) and/or (b), for example a cyclosporin; (d) with water or with an aqueous medium. 
The composition should be essentially free of components which are mixable with water or soluble in water; these are mainly:
  (1) C1-C5-alkyl- or tetrahydrofurfuryl-diether or -partial ethers of low molecular mono- or polyoxy-C1-C12-alkanediols; (2) 1,2-propylene glycol; (3) lower alkanols; (4) esterification products of polycarboxylic acids with 2-10, in particular 3-5 carboxyl groups with C1-C10-alcohols; and (5) esterification products of polyols with 2-10, in particular 3-5 carboxy groups with C2-C11-carboxylic acids; 
Depending from the quantity of the water present W/O microemulsions, bicontinuous microemulsions or O/W microemulsions are obtained.
The microemulsions according to the invention of the O/W type (oil-in-water) have stability properties as they have been described further above in the context of microemulsions, i.e. in particular that in these microemulsions the active ingredient is solubilised in a stable manner, and over several weeks no precipitate may be observed. The particle size of these microemulsions is smaller than 150 nm, preferably smaller than 100 nm.
The microemulsion preconcentrates and microemulsions according to the invention are suitable as a vehicle for substances poorly soluble in water but soluble in component (a) and/or (b), specifically pharmaceutical, biotechnological and cosmetic active ingredients as well as foodstuff active ingredients and cell or tissue culture active ingredients. The microemulsion preconcentrates according to the invention may also contain active ingredients in a finely dispersed form. In their aqueous phase the microemulsions according to the invention may contain water-soluble substances, e.g. water-soluble active ingredients.
One example of a pharmaceutical active ingredient poorly soluble in water but soluble in component (a) and/or (b) is the capillary therapeutic quercetin. The microemulsion preconcentrates and microemulsions according to the invention may however also serve as a vehicle for other pharmaceutical active ingredients poorly soluble in water but soluble in components (a) and/or (b).
One example of a cosmetic active ingredient poorly soluble in water but soluble in component (a) and/or (b) is the anti-wrinkle agent coenzyme Q10. Flavonoides, UV-filters and vitamins are further examples of cosmetic active ingredients.
Examples of biotechnological active ingredients are peptides and proteins, in particular recombinant proteins.
Foodstuff active ingredients are nutrients which also have a preventative or health use. Examples of such foodstuff active ingredients are omega-3 fatty acids (such as EPA and DHA) and vitamins.
Examples of cell or tissue culture active ingredients are vitamins and retinoids.
Microemulsion preconcentrates and microemulsions which contain active ingredients which are poorly soluble in water but soluble in component (a) and/or (b) may be applied for administration in any suitable manner, for example orally in a shape body or a unit dosage form, in particular a soft or hard gelatine capsule. For this administration the compositions according to the invention have shown to be particularly suitable since an addition of volatile organic solvents, in particular of the commonly used ethanol is not necessary. With the application of volatile organic solvents, by way of the evaporation of the solvent through the outer wall of the shape body, in particular the soft or hard gelatine capsule, the storage stability is negatively influenced and the active ingredient crystalises. The occurrence of these negative effects must be avoided by complicated measures on packaging and storage.
Further suitable forms of administration are for example interparenterally or topically, for example for use on the skin, such as a spray, cream, paste, lotion, gel, ointment, pulp packagings, cataplasma, plasters, skin pads and likewise; or for an ophthalmic application, for example in the form of eye drops, eye lotions and eye gels. Slightly flowable forms may also for example be used for an intralesional injection or be administered rectally, for example as an enema. They are however first of all envisaged for an oral, parental or topical application, wherein in the case of a topical application in particular the application on the skin is considered.
Microemulsion preconcentrates envisaged for oral administration, containing an active ingredient poorly soluble in water but soluble in component (a) and/or (b) may on contact with water form a microemulsion with an average particle size of below 150 nm, preferably below 100 nm. Microemulsions which one for example obtains by diluting the microemulsion preconcentrates with water or with an aqueous medium may be used directly as drink formulations. If there is envisaged a topical or parenteral application, then compositions in which further auxiliary agents may be present likewise contain water, so that there results an aqueous microemulsion in the form of a spray, gel or paste, a cream, an injection solution, an infusion solution or likewise.
Preferred embodiments of the microemulsion preconcentrates and microemulsions according to the invention envisaged for topical, in particular dermal application contain additionally one or more of the following components:
    solid hydrocarbons, for example mineral oil gels, such as soft petrolatum or VASELINE, ceresine and solid paraffins, and also waxes, including animal, vegetable and synthetic waxes, such as sperm oil wax, carnauba wax and bee's wax. liquid hydrocarbons, for example liquid paraffins, and fatty acid esters, such as isopropyl myristate and cetyl palmitate. non-volatile silicones, including silicone oils and silicon pastes, as well as copolymerisates of silicone and polyalkylene oxide (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, pages 1109 and 1110, 1989), in particular the products known and obtainable under the description PIROETHICON.   
By way of the application of such additives or of mixtures thereof emulsions may be obtained in liquid or semi-solid form, in dependence of, for example, the requirements for a topical application.
Usefully the compositions envisaged for topical, in particular dermal application additionally contain
    an antioxidant, such as ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopheroles, e.g. D,L-alpha-tocopherole (vitamin E); an anti-bacterial agent, such as benzyl alcohol, methylparabene, propylparabene, benzalconium chloride, benzoic acid, sorbic acid or chlorobutanol; a stabilising agent, such as micro-crystalline starch, sodium EDTA, or magnesium sulphate; an agent for improving the skin penetration, for example 1-dodecylazacycloheptane-2-on which is also known as AZON (Fiedler, Lexikon der Hilfsstoffe (encyclopaedia of auxilary agents), 3rd edition, page 190, 1989).   
A particularly preferred embodiment form of the composition according to the invention envisaged for dermal administration is characterised in that it is obtainable by use of a component (b) containing a polyoxyethylene sorbitane fatty acid ester and/or a polyoxyethylene-glycolated natural or hydrated vegetable oil.
The micro-emulsion preconcentrates according to the invention may be manufactured in that one intimately mixes the individual constituents with one another, where optionally under heating. The micro-emulsion preconcentrates may also be manufactured in that one dissolves the component (b) under stirring, optionally under heating in the component (a), and combines the obtained solution with the component (c) under further stirring.
The microemulsions according to the invention may be manufactured from the microemulsion preconcentrates by diluting with water or other aqueous fluids.
Micro-emulsion preconcentrates according to the invention which are suitable for oral administration are usefully present in a unit dosage form, e.g. in a soft or hard gelatine capsule, and they contain usefully 0.5 to 20, preferably 5-15 percent by weight of an active ingredient poorly in water but soluble in component (a) and/or (b), for example a cyclosporin (component (c)), 9.5 to 70, preferably 20 to 70 percent by weight and further more widely preferred 25 to 65 percent by weight of a mixture consisting of a medium-chain triglyceride and of an omega-9 fatty acid and/or an omega-6 fatty acid (component (a)) and 20 to 90, preferably 25 to 65 percent by weight of the surface-active component (b).
Microemulsion preconcentrates according to the invention, which are suitable for topical or parenteral application usefully contain 0.01 to 15 percent by weight of an active ingredient poorly soluble in water but soluble in component (a) and/or (b), for example a cyclosporin.
In the cyclosporin compositions according to the invention the quantity ratio of omega-9 fatty acids and/or omega-6 fatty acids to the active ingredient is in particular 0.5:1, preferably at least 1:1. In other cases of active ingredients poorly soluble in water but soluble in component (a) and/or (b) the above quantity ratio may be smaller than 0.5:1.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
By way of the following examples the compositions according to the invention are explained further. The examples 1.1 to 1.22 show the manufacture of cyclosporin compositions in oral unit dosage forms, which for example are suitable for the prevention of rejection of transplants or for the treatment of autoimmune diseases. Examples 2.1 to 2.4 show the manufacture of cyclosporin compositions for a topical application which for example are suitable for the treatment of atopical dermatitis or contact dermatitis, psoriasis, balding or certain eye disenses such as conjunctivitis, uveitis or ceratitis. Example 3.1 shows the manufacture of a cylcosporin composition for a parenteral application which is for example suitable for the prevention of a rejection of transplants.
The examples are described with particular reference to cyclosporin A. By way of application of other suitable active ingredients, in particular also other cyclosporins, however comparable compositions may be manufactured.
Example 4 shows the manufacture of a cyclosporin-placebo microemulsion preconcentrate for the oral application and of a cyclosporin placebo 0/W microemulsion for the topical or parenteral application.
Example 5 shows the manufacture of a quercetin microemulsion preconcentrate for oral application as well as the manufacture of a quercetin O/W-microemulsion for the topical or parenteral application
EXAMPLE 1
The Manufacture of Oral Cyclosporin A Dosage Forms of the Microemulsion Preconcentrate Type






 


Example 1.1


 



 




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
35.00%


 
oleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 
 





The cyclosporin A is dissolved under stirring at room temperature is dissolved in the components a1 and a2, and the obtained solution is combined under further heating is displaced with the components b1 and b2. The formed microemulsion preconcentrate is filled into a soft or hard gelatine capsule. Hard gelatine capsules are preferably sealed using the quasi-seal-method. Alternatively the micoemulsion preconcentrate may also be filled into a dispenser. In this case the patient by way of a suitable dilution with water or another aqueous fluid from the microemulsion preconcentrate creates an oral drinking solution of the type O/W microemulsion.
In an analogous manner also the following compositions may be manufactured and filled into capsules or into dispensers.






 



Example 1.2




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.3




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
27.50%


 
oleic acid (a2)
17.50%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.4




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
25.00%


 
oleic acid (a2)
20.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.5




 
cyclosporin A (c)
12.50%


 
Miglyol 812 (a1)
32.50%


 
oleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.6




 
cyclosporin A (c)
12.50%


 
Miglyol 812 (a1)
27.50%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.7




 
cyclosporin A (c)
15.00%


 
Miglyol 812 (a1)
25.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.8




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.9




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
35.00%


 
linoleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.10




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
linoleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.11




 
cyclosporin A (c)
12.50%


 
Miglyol 812 (a1)
27.50%


 
linoleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.12




 
cyclosporin A (c)
15.00%


 
Miglyol 812 (a1)
25.00%


 
linoleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.13




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
25.00%


 
Cremophor RH 40 (b2)
10.00%


 
vitamin E TGPS (b3)
10.00%




Example 1.14




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
25.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor EL (b2)
11.25%




Example 1.15




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
25.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor EL (b2)
11.25%




Example 1.16




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
25.00%


 
Cremophor RH 40 (b2)
10.00%


 
Labrafil M 1944 CS (b3)
10.00%




Example 1.17




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
22.50%


 
Cremophor RH 40 (b2)
22.50%




Example 1.18




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
30.00%


 
linoleic acid (a2)
15.00%


 
Tween 80 (b1)
22.50%


 
Cremophor EL (b2)
22.50%




Example 1.19




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
29.80%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 
D,L-alpha-tocopherol*) 
0.20%




Example 1.20




 
cyclosporin A (c)
10.00%


 
Miglyol 812 (a1)
29.95%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 
ascorbyl palmitate*) 
0.05%




Example 1.21




 
cyclosporin A (c)
5.00%


 
Miglyol 812 (a1)
40.00%


 
oleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%




Example 1.22




 
cyclosporin A (c)
2.50%


 
Miglyol 812 (a1)
42.50%


 
oleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 
 


 
*)antioxidant





If compositions of the above type are diluted with water or another aqueous medium e.g. to 1:100, there arise microemulsions which in the case of representative examples have the following particle sizes:
             Composition O/W-microemulsion       Microemulsion particle size diameter1)  standard deviation1)      preconcentrate [nm] [nm]             Example 1.1 29.0 14.0     Example 1.2 31.7 12.0     Example 1.3 32.0 12.3     Example 1.4 68.3 30.7     Example 1.5 29.5 13.0     Example 1.6 52.3 25.6     Example 1.7 81.6 55.4     Example 1.10 34.1 10.0     Example 1.13 67.7 31.0     Example 1.14 34.7 9.6     Example 1.19 32.6 12.1     Example 1.20 31.9 11.5            1)The particle diameter and particle size distribution (Gauss) are determined by way of laser laserlight scattering (Nicomp 370 Submicron particles Sizer, Volume weighting).     
(1) The particle diameter and particle size distribution (Gauss) are determined by way of laser laserlight scattering (Nicomp 370 Submicron particles Sizer, Volume weighting).

From the subsequent table it is evident that in the case of representative examples the cyclosporin A microemulsions formed from the microemulsion preconcentrates with respect to particle size and distribution have an excellent storage stability. Furthermore during this storage one observes no cyclosporin A precipitates.
           O/W microemulsion     Composition Storage conditions particle standard     Microemulsion time temp. diameter1)  deviation1)    preconcentrate [months]  [Â° C.] [nm] [nm]         Example 1.19 0   32.6 12.1     1 7 4.6 13.3     1 25 35.5 13.4     1 40 37.5 13.3   Example 1.20 0   31.9 11.5     1 7  33.6 14.0     1 25 35.9 14.3     1 40 36.4 13.9        1)The particle diameter and particle size distribution (Gauss) are determined by way of laser laserlight scattering (Nicomp 370 Submicron particles Sizer, Volume weighting).     
(1) The particle diamater and particle size distribution (Gauss) are determined by way of laser laserlight scattering (Nicomp 370 Submicron particles Sizer, Volume weighting).

EXAMPLE 2
The Manufacture of Topically Applicable Cyclosporin A Forms of the Microemulsion Type
The microemulsion preconcentrates described in example 1.1 to 1.22 subsequently serve as a basis for manufacturing sprays, gels, creams and other topical administration forms in that the are further combined with further additives such as water, thickening agents and likewise.






 


Example 2.1: Cylcosporine A 0.25% microemulsions pump spray


 



 




Microemulsion preconcentrate according to Example. 1.21
 
â5.00%


Na2-EDTA
 
â0.10%


benzalkonium chloride
 
â0.01%


10 mM phosphate buffer pH 6
ad
100.00%


 





The microemulsion preceoncentrate is added under stirring at room temperature to the phosphate buffer, containing Na2-EDTA and benzalkonium chloride. The resulting cyclosporin A O/W microemulsion is filled into a pump spray. Instead of the pump spray also pressurised gas and aerosol sprays may be considered.






 


Example 2.2: Cyclosporin A 0.25% hydrogel


 



 




Microemulsion preconcentrate according to Example 1.2
 
â2.50%


Na2-EDTA
 
â0.10%


benzalkonium chloride
 
â0.01%


sodium carboxylmethyl cellulose 450 cp
 
â3.50%


10 mM phosphate buffer pH 6
ad
100.00%


 





The microemulsion preconcentrate is added under stirring is added to the phosphate buffer, containing Na2-EDTA and benzalkonium chloride. The resulting cyclosporin A O/W microemulsion is processed and manufactured in the usual manner with the sodium carboxylmethyl cellulose into the hydrogel.






 


Example 2.3: Cyclosporin A 0.25% O/W emulsion


 



 




Microemulsion preconcentrate according to Example. 1.10
 
â2.500%


isopropyl palmitate
 
â8.000%


glyceryl stearate
 
â7.000%


glycerine
 
â5.000%


stearath-2 + PEG-8 distearate
 
â4.000%


paraffinum liquidum
 
â4.000%


cera microcristallina
 
â4.000%


steareth-21
 
â3.000%


dimethicon
 
â1.000%


benzyl alcohol
 
â0.800%


phenoxy ethanol
 
â0.800%


lanolin alcohol
 
â0.100%


sodium hydroxide
 
â0.005%


water
ad
100.000%


 





The microemulsion preconcentrate is added and mixing to the water phase at room temperature. The resulting cyclosporin A O/W emulsion is processed further and manufactured in the usual manner with the oil phase.






 


Example 2.4: Cyclosporin eye drops


 



 




Microemulsion preconcentrate according to Example. 1.22
 
â4.00%


Na2-EDTA
 
â0.10%


benzalkonium chloride
 
â0.01%


isotonic sodium chloride phosphate buffer pH 7.4
ad
100.00%


 





The microemulsion precocentrate is added under stirring at room temperature to the sodium chloride phosphate buffer, containing Na2-EDTA and benzalkonium chloride. The resulting cylcosporin O/W microemulsion is 0.2 Î¼m sterile filtered and filled in pipette bottles or other usual packings.
EXAMPLE 3
The Manufacture of Parenterally Applicable Cyclosporin A Forms of the Microemulsion Type
The microemulsion preconcentrates described in Example 1.1 to 1.22 may serve as a basis for manufacturing injection or infusion solutions in that they are accordingly diluted with further additives such as physiological sodium chloride solution or 5% glucose solution and likewise.






 


Example 3.1: Cylosporin A 0.25% infusion solution


 



 




microemulsiom preconcentate according to Example 
 
â2.50%


1.19
 
 


5% glucose solution
ad
100.00%


 





The microemulsion preconcentrate is added under stirring at room temperature to the glucose solution. The resulting cyclosporin A O/W microemulsion is 0.2 Î¼m sterile filtered and filled into usual sterile packagings.
EXAMPLE 4






 


Example 4.1 Manufacture of an oral cyclosporin A placebo


dosage form of the type microemulsion preconcentrate


 



 




 
cyclosporin A (c)
0.00%


 
Miglyol 812 (a1)
40.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 





The components (a1), (a2), (b1) and (b2) are mixed under stirring, where appropriate under slight heating. The formed microemulsion preconcentrate is filled into a soft or hard gelatine capsule. Hard gelatine capsules are preferably sealed using the quasi seal method.






 


Example 4.2 Manufacture of a cyclosporin A placebo O/W


microemulsion pump spray for the topical application


 



 




Microemulsion preconcentrate according to Example 4.1
 
â5.00%


Na2-EDTA
 
â0.10%


benzalkonium chloride
 
â0.01%


10 mM phosphate buffer pH 6
ad
100.00%


 





The microemulsion preconcentrate is added under stirring at room temperature is added to the phosphate buffer, containing Na2-EDTA and benzalkonium chloride. The resulting cyclosporin A-placebo O/W microemulsion, with a particle size diameter of 26.8Â±13.4 nm is filled into a pump spray. Instead of the pump spray also pressurised gas and aerolosol sprays are considered.
EXAMPLE 5






 


Example 5.1 Manufacture of an oral quercetin dosage form


of the type microemulsion preconcentrate


 



 




 
quercetin (c)
1.00%


 
Miglyol 812 (a1)
45.00%


 
oleic acid (a2)
9.00%


 
Tween 80 (b1)
45.00%


 





The components (a1), (a2), (b1) are mixed under stirring (e.g. magnetic stirring apparatus) at room temperature. In the resulting clear fluid quercetin is dissolved under stirring (e.g. magnetic stirring apparatus) at room temperature. The formed microemulsion preconcentrate is filled into a soft or hard gelatine capsule. Hard gelatine capsules are preferably sealed using the quasi seal method.






 


Example 5.2 Manufacture of a quercetin O/W microemulsion 


pump spray for the topical application


 



 




Microemulsion preconcentrate according to Example 5.1
 
â10.00%


Na2-EDTA
 
â0.10%


Benzalkonium chloride
 
â0.01%


10 mM phosphate buffer pH 6
ad
100.00%


 





The microemulsion preconcentrate is added under stirring at room temperature is added to the phosphate buffer, containing Na2-EDTA and benzalkonium chloride. The resulting quercetin O/W microemulsion, with a particle size diameter of 34.1Â±15.5 nm is filled into a pump spray. Instead of the pump spray also pressurised gas and aerosol sprays are considered.
EXAMPLE 6
Microemulsion Preconcentrates






 


Example 6.1


 



 




 
Miglyol 812 (a1)
40.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor RH 40 (b2)
11.25%


 





The components a1, a2, b1 and b2 are mixed under stirring (e.g. magnetic stirring apparatus), optionally under slight heating.
In an analogous manner also the following microemulsion preconcentrates may be manufactured:






 



Example 6.2




 
Miglyol 812 (a1)
40.00%


 
oleic acid (a2)
15.00%


 
Tween 80 (b1)
33.75%


 
Cremophor EL (b2)
11.25%




Example 6.3




 
Miglyol 812 (a1)
45.00%


 
oleic acid (a2)
10.00%


 
Tween 80 (b1)
33.75%


 
Cremophor EL (b2)
11.25%




Example 6.4




 
Miglyol 812 (a1)
50.00%


 
oleic acid (a2)
5.00%


 
Tween 80 (b1)
33.75%


 
Cremophor EL (b2)
11.25%




Example 6.5




 
Miglyol 812 (a1)
45.00%


 
oleic acid (a2)
10.00%


 
Cremophor EL (b2)
45.00%




Example 6.6




 
Miglyol 812 (a1)
50.00%


 
oleic acid (a2)
5.00%


 
Tween 80 (b)
45.00%


 
 





The microemulsion preconcentrates described in example 1.1 to 1.6 thereafter serve as a basis for the manufacture of O/W emulsions.




Claims (22)

 
1. A composition in the form of a microemulsion preconcentrate, comprising
(a) a mixture consisting of (i) a fatty acid triglyceride, in which the fatty acid is caprylic acid or capric acid, and (ii) an omega-9 fatty acid and/or an omega-6 fatty acid; and
(b) 20 to 80 percent by weight of a surface-active component, containing a tenside of the polyoxyethylene type

which is essentially free of components mixable with water or components soluble in water, wherein the components comprise esterification products of polycarboxylic acids with 2-10 carboxyl groups with C1-C10 alcohols, and esterification products of polyols with 2-10 hydroxy groups with C2-C11 carboxylic acids.

  
2. A composition in the form of a microemulsion obtained by contacting a microemulsion preconcentrate as recited in claim 1 with water or an aqueous medium.

  
3. A composition according to claim 2, wherein the composition is an oil-in-water microemulsion having an average particle size less than 150 nm.

  
4. A composition according to claim 3, wherein said particle size is less than 100 nm.

  
5. A composition according to claim 2, comprising an active ingredient soluble in water.

  
6. A composition according to claim 1, wherein the omega-9 fatty acid and/or the omega-6 fatty acid comprises 12-24 C-atoms.

  
7. A composition according to claim 1, wherein the omega-9 fatty acid and/or the omega-6 fatty acid comprises 16-24 C-atoms.

  
8. A composition according to claim 1, wherein the omega-9 fatty acid and/or the omega-6 fatty acid comprises 18-22 C-atoms.

  
9. A composition according to claim 8, wherein the omega-9 fatty acid is oleic acid.

  
10. A composition according to claim 8, wherein the omega-6 fatty acid is linoleic acid.

  
11. A composition according to claim 1, wherein the weight ratio of component (ii) to said triglyceride is 1:1 to 1:200.

  
12. A composition according to claim 11, wherein said ratio is 1:2 to 1:20.

  
13. A composition according to claim 1, wherein the surface-active component (b) comprises a polyoxyethylene sorbitane fatty acid ester, a polyoxyethylene-glycolated natural or hydrated vegetable oil or mixtures thereof.

  
14. A composition according to claim 1, wherein the component (a) is present in a quantity of 20 to 70 percent by weight with respect to the total weight of the composition.

  
15. A composition according to claim 1, comprising as component (c) an active ingredient which is soluble in component (a) and/or component (b).

  
16. A composition according to claim 15, wherein the active ingredient is selected from the group of active ingredients which are not soluble or poorly soluble in water but soluble in component (a) and/or component (b).

  
17. A composition according to claim 15, wherein c) is coenzyme Q10.

  
18. A composition according to claim 15, wherein said active ingredient is selected from the group consisting of a pharmaceutical active ingredient, a biotechnological active ingredient, a cosmetic active ingredient, a foodstuff active ingredient and a cell or tissue culture active ingredient, and mixtures thereof.

  
19. A unit dosage form for administering an active ingredient, comprising a composition according to claim 1 or 15.

  
20. A unit dosage form according to claim 19, comprising a biopolymer.

  
21. A unit dosage form according to claim 19, wherein the biopolymer is gelatine.

  
22. A unit dosage form according to claim 19, comprising coenzyme Q10 as component (c).

 




US10/110,212
1999-10-20
2000-10-20
Microemulsion preconcentrate, microemulsion and use thereof 
       
Active
2024-10-22

US8158134B1
            (en)
        

Applications Claiming Priority (3)



Application Number
Priority Date
Filing Date
Title





CH1912/99

1999-10-20



CH191299

1999-10-20



PCT/CH2000/000569

WO2001028520A1
                          (en)
                      
1999-10-20
2000-10-20
Microemulsion preconcentrates, microemulsion and use of such a composition 
       



Publications (1)



Publication Number
Publication Date





US8158134B1
true
US8158134B1
                       (en)
                   

2012-04-17





Family
ID=4221508
Family Applications (1)



Application Number
Title
Priority Date
Filing Date





US10/110,212
Active
2024-10-22

US8158134B1
                          (en)
                      

1999-10-20
2000-10-20
Microemulsion preconcentrate, microemulsion and use thereof 
       



Country Status (9)



Country
Link





US
                (1)
              



US8158134B1
                  (en)
              



EP
                (2)
              
            


EP1408930A1
                  (en)
              



JP
                (1)
              
            


JP4913301B2
                  (en)
              



AT
                (1)
              
            


AT333267T
                  (en)
              



AU
                (3)
              
            


AU7638300A
                  (en)
              



DE
                (1)
              
            


DE50013203D1
                  (en)
              



DK
                (1)
              
            


DK1289502T3
                  (en)
              



ES
                (1)
              
            


ES2267570T3
                  (en)
              



WO
                (3)
              
            


WO2001028518A1
                  (en)
              




Cited By (6)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






EP2845602A4
              (en)
            
*

2012-04-30
2015-12-30
Univ Yonsei Iacf
Cyclosporine-containing, non-irritative nanoemulsion opthalmic composition 
       



US9717703B2
              (en)
            

2009-10-16
2017-08-01
Glaxosmithkline Llc
Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed 
       



WO2020065541A1
              (en)
            

2018-09-25
2020-04-02
Moroccanoil Israel, Ltd.
Microemulsions and methods of use 
       



CN113194927A
              (en)
            
*

2018-11-26
2021-07-30
æµ·å¿æ©å¶è¯å¬å¸
Pharmaceutical formulations of cyclosporin analogs 
       



US11097206B2
              (en)
            

2016-12-09
2021-08-24
Orochem Technologies Inc.
Method for producing purified steviol product using simulated moving bed chromatography 
       



US11465107B2
              (en)
            
*

2019-01-31
2022-10-11
Hong Ngoc Thi Dang
Process for producing a nano omega-3 microemulsion system 
       



Families Citing this family (22)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






DE50211435D1
              (en)
            
*

2001-02-11
2008-02-07
Aquanova Ag

  Process for the preparation of a drug concentrate and drug concentrate
 
     



DE50101395D1
              (en)
            
*

2001-04-12
2004-03-04
Vesifact Ag Baar

  Pharmaceutical formulations containing anti-inflammatory agents and their use
 
     



EP1249230B1
              (en)
            
*

2001-04-12
2003-11-05
Vesifact Ag
Microemulsion-preconcentrates and microemulsions comprising coenzyme Q10 
       



EP1256337A1
              (en)
            
*

2001-05-08
2002-11-13
Vesifact Ag
Method and compositions for applying an agent to a substrate 
       



CN100334106C
              (en)
            

2001-10-19
2007-08-29
ä¼ç´¢æ³°åå°¼å¡è¡ä»½æéå¬å¸
Synthesis of cyclosporin analogs 
       



CA2461730C
              (en)
            
*

2001-10-19
2012-05-15
Isotechnika Inc.
Novel cyclosporin analog microemulsion preconcentrates 
       



DE10158447B4
              (en)
            
*

2001-11-30
2005-02-10
Aquanova German Solubilisate Technologies (Agt) Gmbh

  Ascorbic Solubilisate
 
       



US20040185068A1
              (en)
            
*

2003-03-18
2004-09-23
Zhi-Jian Yu
Self-emulsifying compositions, methods of use and preparation 
       



EP1498143A1
              (en)
            
*

2003-07-18
2005-01-19
Aventis Pharma S.A.
Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids 
       



WO2005089716A1
              (en)
            
*

2004-03-24
2005-09-29
Takeda Pharmaceutical Company Limited
Preparation with elevated content 
       



MX2007000208A
              (en)
            
*

2004-07-01
2007-08-07
Schepens Eye Res Inst
Compositions and methods for treating eye disorders and conditions. 
       



EP1829553A1
              (en)
            
*

2006-02-27
2007-09-05
EnergyBalance AG
Vitamins within mixtures of omega fatty acids 
       



EP1915986A1
              (en)
            

2006-10-23
2008-04-30
BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH
Lipid growth factor formulations 
       



CN101677588A
              (en)
            
*

2007-02-01
2010-03-24
å æ¿å¤§å½å®¶ç ç©¶å§åä¼
formulations of lipophilic bioactive molecules 
     



EP2442805A4
              (en)
            
*

2009-06-19
2012-11-21
Sun Pharma Advanced Res Co Ltd
Nanodispersion of a drug and process for its preparation 
       



EP2301523A1
              (en)
            
*

2009-09-22
2011-03-30
Dr. August Wolff GmbH & Co. KG Arzneimittel
Galenic formulation in colloidal form 
       



ITBS20100017A1
              (en)
            
*

2010-02-03
2011-08-04
Francesco Palladini

  PROCEDURE FOR THE PRODUCTION OF A FOOD AND SUPPLEMENTARY SUPPLEMENTER SO OBTAINED
 
       



KR101008189B1
              (en)
            
*

2010-07-29
2011-01-17
ìì¤ì¨ë°ì´ì¤í ì£¼ìíì¬
Ophthalmic nano-emulsion composition containing cyclosporin for the treatment of dry-eye-syndrome 
       



US20120095098A1
              (en)
            
*

2010-10-18
2012-04-19
Bhiku Patel
Bioavailability Enhancement Delivery System 
       



EP3187172A1
              (en)
            
*

2016-01-04
2017-07-05
Spherium Biomed S.L.
Cyclosporine a topical compositions 
       



WO2019002362A1
              (en)
            
*

2017-06-28
2019-01-03
Spherium Biomed, S.L.
Cyclosporine a topical compositions 
       



CN111228126B
              (en)
            
*

2020-02-17
2022-11-18
éå²åä¸å¤§å­¦
Food-grade polyglycerol monolaurate dilutable microemulsion and preparation method thereof 
       



Citations (19)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






US4732576A
              (en)
            
*

1985-07-13
1988-03-22
Huels Aktiengesellschaft
Motor fuel and fuel oil emulsions using a salt as emulsifier 
       



US5118493A
              (en)
            
*

1986-05-02
1992-06-02
Brigham And Women's Hospital
Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine 
       



US5190748A
              (en)
            
*

1988-11-22
1993-03-02
Hoffmann-La Roche Inc.
Absorption enhancement of antibiotics 
       



WO1993018852A1
              (en)
            

1992-03-16
1993-09-30
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Oil-in-water emulsions of positively charged particles 
       



WO1998015254A1
              (en)
            
*

1996-10-04
1998-04-16
Beiersdorf Ag
Cosmetic or dermatological microemulsion based gels 
       



WO1999029316A1
              (en)
            
*

1997-12-10
1999-06-17
Severson, Mary, L.
Pharmaceutical compositions containing an omega-3 fatty acid oil 
       



WO1999029300A1
              (en)
            

1997-12-10
1999-06-17
Rtp Pharma Inc.
Self-emulsifying fenofibrate formulations 
       



US5925684A
              (en)
            
*

1996-03-11
1999-07-20
Basf Aktiengesellschaft
Stable carotenoid emulsions suitable for parenteral administration 
       



US5929030A
              (en)
            
*

1995-08-30
1999-07-27
Byron Fine Chemicals Inc.
Pharmaceutical compositions 
       



US5932243A
              (en)
            
*

1993-05-27
1999-08-03
Novartis Ag
Galenical formulations 
       



WO1999044642A1
              (en)
            
*

1998-03-05
1999-09-10
Phares Pharmaceutical Research Nv
Pharmaceutical compositions and their use 
       



US5952373A
              (en)
            
*

1994-12-13
1999-09-14
Beiersdorf Ag
Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides 
       



WO1999049848A1
              (en)
            

1998-04-01
1999-10-07
Rtp Pharma Inc.
Anticancer compositions 
       



US5965115A
              (en)
            
*

1997-11-05
1999-10-12
The Procter & Gamble Company
Personal care compositions 
       



US5968495A
              (en)
            
*

1997-11-05
1999-10-19
The Procter & Gamble Company
Personal care compositions 
       



WO1999056727A2
              (en)
            

1998-05-07
1999-11-11
Elan Corporation, Plc
Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems 
       



US6063762A
              (en)
            
*

1997-12-05
2000-05-16
Chong Kun Dang Corp.
Cyclosporin-containing microemulsion preconcentrate composition 
       



US6765020B2
              (en)
            
*

1995-08-07
2004-07-20
Suntory Limited
Drugs for prevention and treatment of diseases caused by abnormalities in cartilage tissues 
       



US20090202596A1
              (en)
            
*

2006-06-13
2009-08-13
Farmatron Limited
Pharmaceutical compositions with biological barriers permeation enhancing properties 
       



Family Cites Families (2)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






IL101387A
              (en)
            
*

1992-03-26
1999-11-30
Pharmos Ltd
Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets 
     



US5660858A
              (en)
            
*

1996-04-03
1997-08-26
Research Triangle Pharmaceuticals
Cyclosporin emulsions 
       





2000


2000-10-17
AU
AU76383/00A
patent/AU7638300A/en
not_active
Abandoned


2000-10-17
WO
PCT/CH2000/000558
patent/WO2001028518A1/en
not_active
Application Discontinuation


2000-10-17
AU
AU76382/00A
patent/AU7638200A/en
not_active
Abandoned


2000-10-17
WO
PCT/CH2000/000559
patent/WO2001028519A1/en
active
Application Filing


2000-10-17
EP
EP00965712A
patent/EP1408930A1/en
not_active
Withdrawn


2000-10-20
ES
ES00967491T
patent/ES2267570T3/en
not_active
Expired - Lifetime


2000-10-20
DE
DE50013203T
patent/DE50013203D1/en
not_active
Expired - Lifetime


2000-10-20
WO
PCT/CH2000/000569
patent/WO2001028520A1/en
active
IP Right Grant


2000-10-20
JP
JP2001531350A
patent/JP4913301B2/en
not_active
Expired - Fee Related


2000-10-20
US
US10/110,212
patent/US8158134B1/en
active
Active



2000-10-20
AU
AU77676/00A
patent/AU7767600A/en
not_active
Abandoned


2000-10-20
DK
DK00967491T
patent/DK1289502T3/en
active



2000-10-20
AT
AT00967491T
patent/AT333267T/en
unknown



2000-10-20
EP
EP00967491A
patent/EP1289502B1/en
not_active
Expired - Lifetime






Patent Citations (20)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






US4732576A
              (en)
            
*

1985-07-13
1988-03-22
Huels Aktiengesellschaft
Motor fuel and fuel oil emulsions using a salt as emulsifier 
       



US5118493A
              (en)
            
*

1986-05-02
1992-06-02
Brigham And Women's Hospital
Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine 
       



US5190748A
              (en)
            
*

1988-11-22
1993-03-02
Hoffmann-La Roche Inc.
Absorption enhancement of antibiotics 
       



WO1993018852A1
              (en)
            

1992-03-16
1993-09-30
Yissum Research Development Company Of The Hebrew University Of Jerusalem
Oil-in-water emulsions of positively charged particles 
       



US5932243A
              (en)
            
*

1993-05-27
1999-08-03
Novartis Ag
Galenical formulations 
       



US5952373A
              (en)
            
*

1994-12-13
1999-09-14
Beiersdorf Ag
Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides 
       



US6765020B2
              (en)
            
*

1995-08-07
2004-07-20
Suntory Limited
Drugs for prevention and treatment of diseases caused by abnormalities in cartilage tissues 
       



US5929030A
              (en)
            
*

1995-08-30
1999-07-27
Byron Fine Chemicals Inc.
Pharmaceutical compositions 
       



US5925684A
              (en)
            
*

1996-03-11
1999-07-20
Basf Aktiengesellschaft
Stable carotenoid emulsions suitable for parenteral administration 
       



WO1998015254A1
              (en)
            
*

1996-10-04
1998-04-16
Beiersdorf Ag
Cosmetic or dermatological microemulsion based gels 
       



US6667044B1
              (en)
            
*

1996-10-04
2003-12-23
Beiersdorf Ag
Cosmetic or dermatological gels based on microemulsions 
       



US5965115A
              (en)
            
*

1997-11-05
1999-10-12
The Procter & Gamble Company
Personal care compositions 
       



US5968495A
              (en)
            
*

1997-11-05
1999-10-19
The Procter & Gamble Company
Personal care compositions 
       



US6063762A
              (en)
            
*

1997-12-05
2000-05-16
Chong Kun Dang Corp.
Cyclosporin-containing microemulsion preconcentrate composition 
       



WO1999029300A1
              (en)
            

1997-12-10
1999-06-17
Rtp Pharma Inc.
Self-emulsifying fenofibrate formulations 
       



WO1999029316A1
              (en)
            
*

1997-12-10
1999-06-17
Severson, Mary, L.
Pharmaceutical compositions containing an omega-3 fatty acid oil 
       



WO1999044642A1
              (en)
            
*

1998-03-05
1999-09-10
Phares Pharmaceutical Research Nv
Pharmaceutical compositions and their use 
       



WO1999049848A1
              (en)
            

1998-04-01
1999-10-07
Rtp Pharma Inc.
Anticancer compositions 
       



WO1999056727A2
              (en)
            

1998-05-07
1999-11-11
Elan Corporation, Plc
Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems 
       



US20090202596A1
              (en)
            
*

2006-06-13
2009-08-13
Farmatron Limited
Pharmaceutical compositions with biological barriers permeation enhancing properties 
       





Non-Patent Citations (5)

* Cited by examiner, â  Cited by third party


Title





Devani et al. "The development and charcterisation of triglycerided-based âspontaneousâ multiple emulsions," in International Journal of Pharmaceutics 300 (2005) 76-88.
*



Devani et al. "The development and charcterisation of triglycerided-based 'spontaneous' multiple emulsions," in International Journal of Pharmaceutics 300 (2005) 76-88.
*



Forster et al. "Influence of microemulsion phases on the preparation of fine disperse emulsions," in Advances in Colloid and Interface Science, vol. 58, No. 2, Jul. 12, 1995, pp. 119-149.
*



John Klier, "Microemulsions," Standard Article, Kirk-Othmer Encyclopedia of Chemical Technology, copyright 1999-2008, abstract.
*



Koga et al. "Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate," in the European Journal of Pharmaceutics and Biopharmaceutics, Vo. 64, 2006, pp. 82-91.
*





Cited By (7)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






US9717703B2
            (en)
          

2009-10-16
2017-08-01
Glaxosmithkline Llc
Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed 
       



US10668038B2
            (en)
          

2009-10-16
2020-06-02
Mochida Pharmaceutical Co., Ltd.
Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed 
       



EP2845602A4
            (en)
          
*

2012-04-30
2015-12-30
Univ Yonsei Iacf
Cyclosporine-containing, non-irritative nanoemulsion opthalmic composition 
       



US11097206B2
            (en)
          

2016-12-09
2021-08-24
Orochem Technologies Inc.
Method for producing purified steviol product using simulated moving bed chromatography 
       



WO2020065541A1
            (en)
          

2018-09-25
2020-04-02
Moroccanoil Israel, Ltd.
Microemulsions and methods of use 
       



CN113194927A
            (en)
          
*

2018-11-26
2021-07-30
æµ·å¿æ©å¶è¯å¬å¸
Pharmaceutical formulations of cyclosporin analogs 
       



US11465107B2
            (en)
          
*

2019-01-31
2022-10-11
Hong Ngoc Thi Dang
Process for producing a nano omega-3 microemulsion system 
       




Also Published As



Publication number
Publication date






AT333267T
              (en)
            

2006-08-15



WO2001028519A1
              (en)
            

2001-04-26



AU7767600A
              (en)
            

2001-04-30



EP1289502B1
              (en)
            

2006-07-19



AU7638300A
              (en)
            

2001-04-30



DE50013203D1
              (en)
            

2006-08-31



ES2267570T3
              (en)
            

2007-03-16



WO2001028520A1
              (en)
            

2001-04-26



DK1289502T3
              (en)
            

2006-11-13



WO2001028518A1
              (en)
            

2001-04-26



EP1408930A1
              (en)
            

2004-04-21



EP1289502A1
              (en)
            

2003-03-12



JP4913301B2
              (en)
            

2012-04-11



AU7638200A
              (en)
            

2001-04-30



JP2003512312A
              (en)
            

2003-04-02





Similar Documents



Publication
Publication Date
Title







US8158134B1
                (en)
              


2012-04-17

Microemulsion preconcentrate, microemulsion and use thereof 
       




AU737053B2
                (en)
              


2001-08-09

Oil-free pharmaceutical compositions containing cyclosporin A 
       




Talegaonkar et al.


2008

Microemulsions: a novel approach to enhanced drug delivery




EP0696920B1
                (en)
              


1998-11-25

Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug 
       




NL194781C
                (en)
              


2003-03-04


  Pharmaceutical preparation for oral administration containing a cyclosporine.
 
     




AU672793B2
                (en)
              


1996-10-17

Pharmaceutical composition containing cyclosporin derivative 
       




JP2012111763A
                (en)
              


2012-06-14

Spontaneously dispersible n-benzoyl staurosporine composition 
       




US6187747B1
                (en)
              


2001-02-13

Pharmaceutical composition comprising cyclosporin 
       




US20040152612A1
                (en)
              


2004-08-05

Coenzyme q10 containing microemulsion preconcentrates and microemulsions 
       




EP0985412B1
                (en)
              


2004-10-27

Cyclosporin compositions 
       




EP1151755B1
                (en)
              


2005-03-16

Pharmaceutical compositions comprising cyclosporin as active ingredient 
       




US6346511B1
                (en)
              


2002-02-12

Pharmaceutical composition comprising cyclosporin 
       




ES2215101T3
                (en)
              


2004-10-01


  PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-INFLAMMATORY ACTIVE PRODUCTS, AND THEIR EMPLOYMENT.
 
     




JP2006509785A
                (en)
              


2006-03-23


  Oral microemulsion composition of biphenyldimethyldicarboxylic acid
 
       




AU762247B2
                (en)
              


2003-06-19

Oil-free pharmaceutical compositions containing cyclosporin A 
       




MXPA99006916A
                (en)
              


2000-01-01

Oil-free pharmaceutical compositions containing cyclosporin a 
       




AU4448602A
                (en)
              


2002-07-18

Hydrophilic binary systems for the administration of cyclosporine 
     





Legal Events



Date
Code
Title
Description




2002-04-19
AS
Assignment


Owner name:
              VESIFACT AG, SWITZERLAND


Free format text:
              ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUPERSAXO, ANDREAS;REEL/FRAME:013027/0323


Effective date:
              20020412




2012-03-28
STCF
Information on status: patent grant


Free format text:
              PATENTED CASE




2015-09-30
FPAY
Fee payment


Year of fee payment:
              4




2019-10-04
MAFP
Maintenance fee payment


Free format text:
              PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY


Year of fee payment:
              8














